CN111875614B - Heterocyclyl-substituted thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -diones and their use - Google Patents
Heterocyclyl-substituted thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -diones and their use Download PDFInfo
- Publication number
- CN111875614B CN111875614B CN202010636105.1A CN202010636105A CN111875614B CN 111875614 B CN111875614 B CN 111875614B CN 202010636105 A CN202010636105 A CN 202010636105A CN 111875614 B CN111875614 B CN 111875614B
- Authority
- CN
- China
- Prior art keywords
- compound
- compounds
- group
- formula
- atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JGOOQALRLGHKIY-UHFFFAOYSA-N 1h-thieno[2,3-d]pyrimidine-2,4-dione Chemical class O=C1NC(=O)NC2=C1C=CS2 JGOOQALRLGHKIY-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 188
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 230000001419 dependent effect Effects 0.000 claims abstract description 17
- 239000003163 gonadal steroid hormone Substances 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 10
- 206010046798 Uterine leiomyoma Diseases 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 201000009273 Endometriosis Diseases 0.000 claims abstract description 6
- 201000010260 leiomyoma Diseases 0.000 claims abstract description 6
- 208000006155 precocious puberty Diseases 0.000 claims abstract description 6
- -1 carrier Substances 0.000 claims description 97
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 21
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 229910052805 deuterium Inorganic materials 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 7
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 230000002611 ovarian Effects 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 201000004384 Alopecia Diseases 0.000 claims description 3
- 201000000736 Amenorrhea Diseases 0.000 claims description 3
- 206010001928 Amenorrhoea Diseases 0.000 claims description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 3
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 206010036049 Polycystic ovaries Diseases 0.000 claims description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 231100000360 alopecia Toxicity 0.000 claims description 3
- 231100000540 amenorrhea Toxicity 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 208000000509 infertility Diseases 0.000 claims description 3
- 231100000535 infertility Toxicity 0.000 claims description 3
- 230000036512 infertility Effects 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 3
- 201000004240 prostatic hypertrophy Diseases 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 30
- 238000000034 method Methods 0.000 abstract description 20
- 206010060862 Prostate cancer Diseases 0.000 abstract description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 abstract description 3
- 229940127445 Gonadotropin Releasing Hormone Receptor Antagonists Drugs 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
- 125000004432 carbon atom Chemical group C* 0.000 description 45
- 125000004429 atom Chemical group 0.000 description 40
- 150000003254 radicals Chemical class 0.000 description 34
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 230000015572 biosynthetic process Effects 0.000 description 26
- 125000001072 heteroaryl group Chemical group 0.000 description 26
- 239000007787 solid Substances 0.000 description 25
- 238000003786 synthesis reaction Methods 0.000 description 25
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 19
- 238000000132 electrospray ionisation Methods 0.000 description 19
- 238000004949 mass spectrometry Methods 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- 150000002500 ions Chemical class 0.000 description 17
- 125000003118 aryl group Chemical group 0.000 description 16
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 13
- 125000003277 amino group Chemical group 0.000 description 13
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 125000000753 cycloalkyl group Chemical group 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 125000002947 alkylene group Chemical group 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 11
- 229940002612 prodrug Drugs 0.000 description 11
- 239000000651 prodrug Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 description 10
- 125000003545 alkoxy group Chemical group 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- 229940088597 hormone Drugs 0.000 description 10
- 239000005556 hormone Substances 0.000 description 10
- 125000006413 ring segment Chemical group 0.000 description 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 230000003042 antagnostic effect Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 229910052801 chlorine Inorganic materials 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 229910052731 fluorine Inorganic materials 0.000 description 9
- 239000002207 metabolite Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 150000008513 pyrimidine-2,4(1H,3H)-diones Chemical class 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 125000004414 alkyl thio group Chemical group 0.000 description 8
- 229910052794 bromium Inorganic materials 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 229910052740 iodine Inorganic materials 0.000 description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 7
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 239000012453 solvate Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108700012941 GNRH1 Proteins 0.000 description 6
- 102000008238 LHRH Receptors Human genes 0.000 description 6
- 108010021290 LHRH Receptors Proteins 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 6
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 5
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 125000003282 alkyl amino group Chemical group 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 230000002980 postoperative effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- 108010024118 Hypothalamic Hormones Proteins 0.000 description 4
- 102000015611 Hypothalamic Hormones Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 4
- 125000002393 azetidinyl group Chemical group 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 229940043650 hypothalamic hormone Drugs 0.000 description 4
- 239000000601 hypothalamic hormone Substances 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 125000002757 morpholinyl group Chemical group 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- 125000004193 piperazinyl group Chemical group 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 125000003373 pyrazinyl group Chemical group 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 125000002098 pyridazinyl group Chemical group 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 125000000168 pyrrolyl group Chemical group 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 3
- KWWYRWMRSFVNEW-UHFFFAOYSA-N 6-(4-aminophenyl)-1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(oxan-4-yl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4CCOCC4)C5=CC=C(C=C5)N KWWYRWMRSFVNEW-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 108010069236 Goserelin Proteins 0.000 description 3
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 239000003329 adenohypophysis hormone Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 3
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000002474 gonadorelin antagonist Substances 0.000 description 3
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 3
- 229960002913 goserelin Drugs 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 3
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- YNVOMSDITJMNET-UHFFFAOYSA-M thiophene-3-carboxylate Chemical compound [O-]C(=O)C=1C=CSC=1 YNVOMSDITJMNET-UHFFFAOYSA-M 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- JHSAOVNIXNGOCW-UHFFFAOYSA-N 1-methyl-2-(2-propan-2-ylazirin-1-yl)-7H-purin-6-one Chemical compound CC(C)C1=CN1C(N(C1=O)C)=NC2=C1NC=N2 JHSAOVNIXNGOCW-UHFFFAOYSA-N 0.000 description 2
- MJXRENZUAQXZGJ-UHFFFAOYSA-N 2-(chloromethyl)-1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1CCl MJXRENZUAQXZGJ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- XIJMFDLNBMQHFI-UHFFFAOYSA-N 6-(4-aminophenyl)-1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(1,1-dioxothian-4-yl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4CCS(=O)(=O)CC4)C5=CC=C(C=C5)N XIJMFDLNBMQHFI-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108010037003 Buserelin Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 2
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 2
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 2
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 2
- 108010023617 abarelix Proteins 0.000 description 2
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 2
- 229960002184 abarelix Drugs 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 125000005997 bromomethyl group Chemical group 0.000 description 2
- 229960002719 buserelin Drugs 0.000 description 2
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 108700008462 cetrorelix Proteins 0.000 description 2
- 229960003230 cetrorelix Drugs 0.000 description 2
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 108700025485 deslorelin Proteins 0.000 description 2
- 229960005408 deslorelin Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 108700032141 ganirelix Proteins 0.000 description 2
- 229960003794 ganirelix Drugs 0.000 description 2
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229960001442 gonadorelin Drugs 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 108700020746 histrelin Proteins 0.000 description 2
- 229960002193 histrelin Drugs 0.000 description 2
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 2
- MGIODZWPWVYAOR-UHFFFAOYSA-N phenyl n-cyclopropylcarbamate Chemical compound C=1C=CC=CC=1OC(=O)NC1CC1 MGIODZWPWVYAOR-UHFFFAOYSA-N 0.000 description 2
- WCMDBGGJBGZLDL-UHFFFAOYSA-N phenyl n-methoxycarbamate Chemical compound CONC(=O)OC1=CC=CC=C1 WCMDBGGJBGZLDL-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 230000002483 superagonistic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- YNVOMSDITJMNET-UHFFFAOYSA-N thiophene-3-carboxylic acid Chemical class OC(=O)C=1C=CSC=1 YNVOMSDITJMNET-UHFFFAOYSA-N 0.000 description 2
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960004824 triptorelin Drugs 0.000 description 2
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- HJNZCKLMRAOTMA-BRBGIFQRSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(2-methyl-1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydr Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=C(C)NC2=CC=CC=C12 HJNZCKLMRAOTMA-BRBGIFQRSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- KZKYCKOUODFYBV-UHFFFAOYSA-N 1,1-dioxothian-4-amine Chemical compound NC1CCS(=O)(=O)CC1 KZKYCKOUODFYBV-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FLJOZKZJBZONPR-UHFFFAOYSA-N 1-[(2,6-difluorophenyl)methyl]-3-(1,1-dioxothian-4-yl)-5-methyl-6-(4-nitrophenyl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4CCS(=O)(=O)CC4)C5=CC=C(C=C5)[N+](=O)[O-] FLJOZKZJBZONPR-UHFFFAOYSA-N 0.000 description 1
- AYLYBGBQLMZMEY-UHFFFAOYSA-N 1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(1,1-dioxothian-4-yl)-6-(4-nitrophenyl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4CCS(=O)(=O)CC4)C5=CC=C(C=C5)[N+](=O)[O-] AYLYBGBQLMZMEY-UHFFFAOYSA-N 0.000 description 1
- YZTYMTPTTCOWLT-UHFFFAOYSA-N 1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-6-(4-nitrophenyl)-3-(oxan-4-yl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4CCOCC4)C5=CC=C(C=C5)[N+](=O)[O-] YZTYMTPTTCOWLT-UHFFFAOYSA-N 0.000 description 1
- CVMHMATXOLTCNE-UHFFFAOYSA-N 1-[(2,6-difluorophenyl)methyl]-5-methyl-6-(4-nitrophenyl)-3-(oxan-4-yl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4CCOCC4)C5=CC=C(C=C5)[N+](=O)[O-] CVMHMATXOLTCNE-UHFFFAOYSA-N 0.000 description 1
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 108010070743 3(or 17)-beta-hydroxysteroid dehydrogenase Proteins 0.000 description 1
- JPJDBPHMHCZGBH-UHFFFAOYSA-N 3-(1,1-dioxothian-4-yl)-5-methyl-6-(4-nitrophenyl)-1H-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC1=C(SC2=C1C(=O)N(C(=O)N2)C3CCS(=O)(=O)CC3)C4=CC=C(C=C4)[N+](=O)[O-] JPJDBPHMHCZGBH-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- YQYGPGKTNQNXMH-UHFFFAOYSA-N 4-nitroacetophenone Chemical compound CC(=O)C1=CC=C([N+]([O-])=O)C=C1 YQYGPGKTNQNXMH-UHFFFAOYSA-N 0.000 description 1
- BQRNUDUKWIAWPE-UHFFFAOYSA-N 5-(bromomethyl)-1-[(2,6-difluorophenyl)methyl]-3-(1,1-dioxothian-4-yl)-6-(4-nitrophenyl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound C1CS(=O)(=O)CCC1N2C(=O)C3=C(N(C2=O)CC4=C(C=CC=C4F)F)SC(=C3CBr)C5=CC=C(C=C5)[N+](=O)[O-] BQRNUDUKWIAWPE-UHFFFAOYSA-N 0.000 description 1
- MKNYHPMSNJJJLT-UHFFFAOYSA-N 5-(bromomethyl)-1-[(2,6-difluorophenyl)methyl]-6-(4-nitrophenyl)-3-(oxan-4-yl)thieno[2,3-d]pyrimidine-2,4-dione Chemical compound C1COCCC1N2C(=O)C3=C(N(C2=O)CC4=C(C=CC=C4F)F)SC(=C3CBr)C5=CC=C(C=C5)[N+](=O)[O-] MKNYHPMSNJJJLT-UHFFFAOYSA-N 0.000 description 1
- BECOTVMJRGJHON-UHFFFAOYSA-N 5-methyl-6-(4-nitrophenyl)-3-(oxan-4-yl)-1H-thieno[2,3-d]pyrimidine-2,4-dione Chemical compound CC1=C(SC2=C1C(=O)N(C(=O)N2)C3CCOCC3)C4=CC=C(C=C4)[N+](=O)[O-] BECOTVMJRGJHON-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000000827 Anterior Pituitary Hormones Human genes 0.000 description 1
- 108010001897 Anterior Pituitary Hormones Proteins 0.000 description 1
- 229930091051 Arenine Natural products 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100034067 Dehydrogenase/reductase SDR family member 11 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 150000007945 N-acyl ureas Chemical class 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 101000783356 Naja sputatrix Cytotoxin Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010074268 Reproductive toxicity Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical group [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 102100029469 WD repeat and HMG-box DNA-binding protein 1 Human genes 0.000 description 1
- 101710097421 WD repeat and HMG-box DNA-binding protein 1 Proteins 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 239000002340 cardiotoxin Substances 0.000 description 1
- 231100000677 cardiotoxin Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- CXRJNUVDWUINBY-UHFFFAOYSA-N ethyl 2-amino-4-methyl-5-(4-nitrophenyl)thiophene-3-carboxylate Chemical compound CCOC(=O)C1=C(N)SC(C=2C=CC(=CC=2)[N+]([O-])=O)=C1C CXRJNUVDWUINBY-UHFFFAOYSA-N 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003037 female contraceptive agent Substances 0.000 description 1
- 229940124566 female contraceptive agent Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000007674 genetic toxicity Effects 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007916 intrasternal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 108010080415 lecirelin Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002583 male contraceptive agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 108700025096 meterelin Proteins 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical group OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Chemical group 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 231100000372 reproductive toxicity Toxicity 0.000 description 1
- 230000007696 reproductive toxicity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000010579 uterine corpus leiomyoma Diseases 0.000 description 1
- 201000007954 uterine fibroid Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicines, and relates to heterocyclic group substituted thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -diketone compounds, application thereof and a pharmaceutical composition containing the compounds, which can be used as gonadotropin releasing hormone receptor antagonists. The invention also relates to methods for preparing such compounds and pharmaceutical compositions, and their use in the prevention or treatment of sex hormone dependent diseases, including but not limited to prostate cancer, endometriosis, uterine fibroids, precocious puberty, and the like.
Description
Technical Field
The invention belongs to the technical field of medicines, and relates to a compound and a pharmaceutical composition for preventing or treating sex hormone-dependent diseases, and a using method and application thereof. In particular, the invention relates to heterocyclic group substituted thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -diones which can be used as gonadotropin releasing hormone receptor antagonists and uses thereof.
Background
The secretion of anterior pituitary hormone is feedback-controlled by peripheral hormones secreted from the target organs of the respective hormones and by secretion-regulating hormones from the hypothalamus, which is the upper central organ of the anterior pituitary (hereinafter, these hormones are collectively referred to as "hypothalamic hormones" in the specification). Currently, it has been confirmed that as hypothalamic hormones, there are nine hormones including, for example, thyrotropin-releasing hormone (TRH) and gonadotropin-releasing hormone (GnRH, sometimes referred to as LH-RH (luteinizing hormone-releasing hormone)). These hypothalamic hormones are thought to exhibit their effects via receptors that are thought to be present in the anterior pituitary; and efforts have been made to find receptor-gene expression specific for these hormones, including in humans. Thus, antagonists or agonists that specifically and selectively act on these receptors should control the action of hypothalamic hormones and the secretion of anterior pituitary hormones. Therefore, such antagonists or agonists are expected to be useful for the prevention or treatment of anterior pituitary hormone-dependent diseases.
Most of the compounds having GnRH antagonistic activity known so far are peptide compounds, for example, GnRH-derived linear peptides (linear peptides) (US 5,140,009 and US 5,171,835), bicyclic peptide derivatives (Journal of Medicinal Chemistry, Vol.36, pp. 3265-3273(1993)), decapeptide compounds modified at position 5 or 6 (WO 9846634A1) and decapeptide compounds modified at position 8 (EP 0277829B 1), and the like.
Peptide compounds present a number of problems to be solved, which are associated with oral absorbability, dosage form, dose volume, drug stability, sustained action, metabolic stability, and the like. Therefore, there is a strong need for an oral GnRH antagonist, particularly an antagonist based on a non-peptide compound, which has an excellent therapeutic effect on sex hormone-dependent diseases such as prostate cancer, endometriosis, precocious puberty and the like, which exhibits not only an instant pituitary-gonadotropic action (acute action) but also excellent oral absorbability.
Disclosure of Invention
The following is a summary of some aspects of the invention only and is not intended to be limiting. These aspects and others are described more fully below. All references in this specification are incorporated herein by reference in their entirety. When the disclosure of the present specification differs from the cited documents, the disclosure of the present specification controls.
The invention relates to a novel heterocyclic group substituted thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -diketone compound, which has unexpected excellent GnRH antagonistic activity and can be used as a gonadotropin releasing hormone receptor antagonist so as to be used for preventing or treating sex hormone dependent diseases, including but not limited to prostate cancer, endometriosis, uterine fibroids, precocious puberty and the like.
The compound has stable property and good safety, and has the advantages of pharmacodynamics and pharmacokinetics, such as good brain/plasma ratio (brain plasma ratio), good bioavailability or good metabolic stability and the like, so the compound has good clinical application prospect.
The invention also provides processes for the preparation of such compounds and pharmaceutical compositions containing them.
In one aspect, the invention relates to a compound that is a compound of formula (I) or a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt of a compound of formula (I) or a prodrug thereof,
wherein R is1、R2a、R2b、R2c、R2d、R3、R4、R5a、R5b、R5c、R5d、R5e、R6a、R6b、R6c、R6dAnd X has the meaning as described in the present invention.
In some embodiments, X is O, S, NR, S (═ O), or S (═ O)2(ii) a Wherein R has the meaning as defined in the description.
In some embodiments, R is H, D, -C (═ O) - (C)1-C6Alkyl group), C1-C6Alkyl radical, C2-C6Alkenyl radical, C2-C6Alkynyl, C1-C6Haloalkyl, hydroxy-substitutedC of (A)1-C6Alkyl radical, C3-6Cycloalkyl, heterocyclic group consisting of 3 to 8 atoms, C6-10Aryl or heteroaryl of 5 to 10 atoms.
In some embodiments, R1Is C1-C6Alkyl radical, C2-C6Alkenyl radical, C2-C6Alkynyl, C1-C6Haloalkyl, C1-C6Alkoxy radical, C1-C6Haloalkoxy, hydroxy-substituted C1-C6Alkyl, cyano-substituted C1-C6Alkyl, amino substituted C1-C6Alkyl radical, C3-6Cycloalkyl, heterocyclic group consisting of 3 to 8 atoms, C6-10Aryl or heteroaryl of 5 to 10 atoms.
In some embodiments, each R is2a、R2b、R2c、R2d、R6a、R6b、R6cAnd R6dIndependently H, D, F, Cl, Br, I, -CN, -NO2、-NH2、-OH、-SH、-COOH、-C(=O)NH2、-C(=O)NHCH3、-C(=O)N(CH3)2、-C(=O)-(C1-C6Alkyl), -C (═ O) - (C)1-C6Alkoxy group), C1-C6Alkyl radical, C2-C6Alkenyl radical, C2-C6Alkynyl, C1-C6Haloalkyl, C1-C6Alkoxy radical, C1-C6Haloalkoxy, C1-C6Alkylthio radical, C1-C6Alkylamino, hydroxy-substituted C1-C6Alkyl radical, C3-6Cycloalkyl, heterocyclic group consisting of 3 to 8 atoms, C6-10Aryl or heteroaryl of 5 to 10 atoms.
In some embodiments, R3And R4Each independently is H, D, -OH, C1-C6Alkyl radical, C2-C6Alkenyl radical, C2-C6Alkynyl, C1-C6Haloalkyl, C1-C6Alkoxy radical, C1-C6Haloalkoxy, C3-6Cycloalkyl, heterocyclic group consisting of 3 to 8 atoms, C6-10Aryl, heteroaryl of 5 to 10 atoms, C3-6Cycloalkyl radical C1-6Alkylene, (heterocyclic group consisting of 3 to 8 atoms) C1-6Alkylene radical, C6-10Aryl radical C1-6Alkylene or (heteroaryl of 5 to 10 atoms) C1-6An alkylene group.
In some embodiments, R5a、R5b、R5c、R5dAnd R5eEach independently is H, D, F, Cl, Br, I, -CN, -NO2、-NH2、 -OH、-SH、-COOH、-C(=O)NH2、-C(=O)NHCH3、-C(=O)N(CH3)2、-C(=O)-(C1-C6Alkyl), -C (═ O) - (C)1-C6Alkoxy), -NHS (═ O)2C1-C6Alkyl, -N (C)1-6Alkyl) S (═ O)2C1-C6Alkyl, -S (═ O)2C1-C6Alkyl radical, C1-C6Alkyl radical, C2-C6Alkenyl radical, C2-C6Alkynyl, C1-C6Haloalkyl, C1-C6Alkoxy radical, C1-C6Haloalkoxy, C1-C6Alkylthio radical, C1-C6Alkylamino, hydroxy-substituted C1-C6Alkyl radical, C3-6Cycloalkyl, heterocyclic group consisting of 3 to 8 atoms, C6-10Aryl or heteroaryl of 5 to 10 atoms.
In some embodiments, R is H, D, -C (═ O) - (C)1-C4Alkyl group), C1-C4Alkyl radical, C2-C4Alkenyl radical, C2-C4Alkynyl, C1-C4Haloalkyl, hydroxy-substituted C1-C4Alkyl radical, C3-6Cycloalkyl, heterocyclic group consisting of 3 to 6 atoms, C6-10Aryl or heteroaryl of 5 to 6 atoms.
In other embodiments, R is H, D, -C (═ O) -CH3Methyl, ethyl, n-butylPropyl, isopropyl, n-butyl, tert-butyl, 2-methylpropyl, 1-methylpropyl, ethenyl, ethynyl, -CHF2、-CF3Hydroxymethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, tetrahydrofuryl, piperidinyl, piperazinyl, morpholinyl, phenyl, indenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl.
In some embodiments, R1Is C1-C4Alkyl radical, C2-C4Alkenyl radical, C2-C4Alkynyl, C1-C4Haloalkyl, C1-C4Alkoxy radical, C1-C4Haloalkoxy, hydroxy-substituted C1-C4Alkyl, cyano-substituted C1-C4Alkyl, amino substituted C1-C4Alkyl radical, C3-6Cycloalkyl, heterocyclic group consisting of 3 to 6 atoms, C6-10Aryl or heteroaryl of 5 to 6 atoms.
In other embodiments, R1Is methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, 2-methylpropyl, 1-methylpropyl, ethenyl, propenyl, allyl, ethynyl, propynyl, propargyl, -CHF2、-CF3、-CHFCH2F、-CF2CHF2、-CH2CHF2、 -CH2CF3、-CH2CF2CHF2Methoxy, ethoxy, isopropoxy, -OCF3Hydroxymethyl, 2-hydroxyethyl, -CH2CN、-CH2CH2CN、 -CH2CH2CH2CN、-CH2NH2、-CH2CH2NH2、-CH2CH2CH2NH2Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, indenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, and trisAn azolyl, tetrazolyl, furyl, thienyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl, or pyridazinyl group.
In some embodiments, each R is2a、R2b、R2c、R2d、R6a、R6b、R6cAnd R6dIndependently H, D, F, Cl, Br, I, -CN, -NO2、-NH2、-OH、-SH、-COOH、-C(=O)NH2、-C(=O)NHCH3、-C(=O)N(CH3)2、-C(=O)-(C1-C4Alkyl), -C (═ O) - (C)1-C4Alkoxy group), C1-C4Alkyl radical, C2-C4Alkenyl radical, C2-C4Alkynyl, C1-C4Haloalkyl, C1-C4Alkoxy radical, C1-C4Haloalkoxy, C1-C4Alkylthio radical, C1-C4Alkylamino or hydroxy substituted C1-C4An alkyl group.
In other embodiments, each R is2a、R2b、R2c、R2d、R6a、R6b、R6cAnd R6dIndependently H, D, F, Cl, Br, I, -CN, -NO2、-NH2、-OH、-SH、-COOH、-C(=O)NH2、-C(=O)NHCH3、-C(=O)N(CH3)2、-C(=O)-CH3、 -C(=O)-OCH3Methyl, ethyl, n-propyl, isopropyl, tert-butyl, vinyl, -CHF2、-CF3Methoxy, -OCF3Methylamino, dimethylamino or hydroxymethyl.
In some embodiments, R3And R4Each independently is H, D, -OH, C1-C4Alkyl radical, C2-C4Alkenyl radical, C2-C4Alkynyl, C1-C4Haloalkyl, C1-C4Alkoxy radical, C1-C4Haloalkoxy, C3-6Cycloalkyl, heterocyclic group consisting of 3 to 6 atoms, C6-10Aryl, 5-6 atomsSub-constituent heteroaryl, C3-6Cycloalkyl radical C1-4Alkylene, (heterocyclic group consisting of 3 to 6 atoms) C1-4Alkylene radical, C6-10Aryl radical C1-4Alkylene or (heteroaryl of 5 to 6 atoms) C1-4An alkylene group.
In other embodiments, R3And R4Each independently H, D, -OH, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, 2-methylpropyl, 1-methylpropyl, ethenyl, propenyl, allyl, ethynyl, propynyl, propargyl, -CHF2、-CF3Methoxy, ethoxy, isopropoxy, -OCF3Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, indenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, C3-6Cycloalkyl methylene, C3-6Cycloalkylethylene radical, C3-6Cycloalkylpropylene, (heterocyclyl) methylene of 3-6 atoms, (heterocyclyl) ethylene of 3-6 atoms, phenylmethylene, phenylethylene, phenylpropylene, pyridylmethylene, pyrimidylmethylene, pyrrolylmethylene, pyrazolyl methylene, triazolylmethylene or tetrazolylmethylene.
In some embodiments, R5a、R5b、R5c、R5dAnd R5eEach independently is H, D, F, Cl, Br, I, -CN, -NO2、-NH2、-OH、-SH、-COOH、-C(=O)NH2、-C(=O)NHCH3、-C(=O)N(CH3)2、-C(=O)-(C1-C4Alkyl), -C (═ O) - (C)1-C4Alkoxy), -S (═ O)2C1-C4Alkyl radical, C1-C4Alkyl radical, C2-C4Alkenyl radical, C2-C4Alkynyl, C1-C4Haloalkyl, C1-C4Alkoxy radical, C1-C4Haloalkoxy, C1-C4Alkylthio radical, C1-C4Alkylamino or hydroxy substituted C1-C4An alkyl group.
In other embodiments, R5a、R5b、R5c、R5dAnd R5eEach independently is H, D, F, Cl, Br, I, -CN, -NO2、 -NH2、-OH、-SH、-COOH、-C(=O)NH2、-C(=O)NHCH3、-C(=O)N(CH3)2、-C(=O)-CH3、-C(=O)-OCH3、 -S(=O)2CH3Methyl, ethyl, n-propyl, isopropyl, tert-butyl, vinyl, -CHF2、-CF3Methoxy, -OCF3Methylamino, dimethylamino or hydroxymethyl.
In some embodiments, the compound of the present invention, which is a compound of formula (II) or a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt of a compound of formula (II), or a prodrug thereof,
wherein R is1、R3、R4And X has the meaning as described in the present invention.
In some embodiments, the compound of the present invention is a compound having one of the following structures or a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt of the compound having one of the following structures, or a prodrug thereof:
in another aspect, the present invention relates to a pharmaceutical composition comprising a compound disclosed herein.
In some embodiments, the pharmaceutical composition of the present invention further comprises a pharmaceutically acceptable excipient, carrier, adjuvant, or any combination thereof.
In another aspect, the invention relates to the use of a compound or pharmaceutical composition disclosed herein for the manufacture of a medicament for the prevention or treatment of a sex hormone dependent disease.
In some embodiments, the sex hormone dependent disorder of the invention is a sex hormone dependent cancer, a bone metastasis of a sex hormone dependent cancer, prostatic hypertrophy, uterine fibroids, endometriosis, uterine fibroids, precocious puberty, amenorrhea, premenstrual syndrome, dysmenorrhea, multiple atrial ovarian syndrome, polycystic ovarian syndrome, acne, alopecia, alzheimer's disease, infertility, irritable bowel syndrome, a benign or malignant tumor that is hormone independent and sensitive to LH-RH (luteinizing hormone releasing hormone), or flushing.
In one aspect, the invention relates to the use of a compound or pharmaceutical composition disclosed herein for the manufacture of a medicament useful as a reproduction regulator (reproduction regulator), a contraceptive, an ovulation inducer (ovulation indicator), or for the prevention of postoperative recurrence of sex hormone dependent cancer.
In another aspect, the invention relates to the use of a compound or pharmaceutical composition disclosed herein for the manufacture of a medicament for antagonizing gonadotropin releasing hormone (GnRH).
In another aspect, the invention relates to methods for the preparation, isolation and purification of compounds of formula (I) or formula (II).
Biological test results show that the compound has stronger antagonistic activity on gonadotropin releasing hormone (GnRH), so that the compound provided by the invention can be used as a better GnRH antagonist.
Any embodiment of any aspect of the invention may be combined with other embodiments, as long as they do not contradict. Furthermore, in any embodiment of any aspect of the invention, any feature may be applicable to that feature in other embodiments, so long as they do not contradict.
Detailed description of the invention
Definitions and general terms
Reference will now be made in detail to certain embodiments of the invention, examples of which are illustrated by the accompanying structural and chemical formulas. The invention is intended to cover alternatives, modifications and equivalents, which may be included within the scope of the invention as defined by the appended claims. One skilled in the art will recognize that many methods and materials similar or equivalent to those described herein can be used in the practice of the present invention. The present invention is in no way limited to the methods and materials described herein. In the event that one or more of the incorporated documents, patents, and similar materials differ or contradict this application (including but not limited to defined terminology, application of terminology, described techniques, and the like), this application controls.
It will be further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.
The following definitions, as used herein, should be applied unless otherwise indicated. For the purposes of the present invention, the chemical elements are in accordance with the CAS version of the periodic Table of the elements, and the handbook of chemistry and Physics, 75 th edition, 1994. In addition, general principles of Organic Chemistry can be referred to as described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausaltito: 1999, and "March's Advanced Organic Chemistry" by Michael B. Smith and Jerry March, John Wiley & Sons, New York:2007, the entire contents of which are incorporated herein by reference.
The articles "a," "an," and "the" as used herein are intended to include "at least one" or "one or more" unless otherwise indicated or clearly contradicted by context. Thus, as used herein, the articles refer to one or to more than one (i.e., to at least one) of the objects. For example, "a component" refers to one or more components, i.e., there may be more than one component contemplated for use or use in embodiments of the described embodiments.
The term "patient" as used herein refers to humans (including adults and children) or other animals. In some embodiments, "patient" refers to a human.
The term "stereoisomers" refers to compounds having the same chemical structure, but differing in the arrangement of atoms or groups in space. Stereoisomers include enantiomers, diastereomers, conformers (rotamers), geometric (cis/trans) isomers, atropisomers, and the like.
The term "tautomer" or "tautomeric form" refers to structural isomers having different energies that can interconvert by a low energy barrier (low energy barrier). If tautomerism is possible (e.g., in solution), then the chemical equilibrium of the tautomer can be reached. For example, proton tautomers (also known as proton transfer tautomers) include interconversions by proton migration, such as keto-enol isomerization and imine-enamine isomerization.
"pharmaceutically acceptable" refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio, and which are effective for their intended use.
The term "optionally substituted with … …" is used interchangeably with the term "unsubstituted or substituted with … …", i.e., the structure is unsubstituted or substituted with one or more substituents described herein, including but not limited to D, F, Cl, Br, I, N3, -CN,-NO2,-NH2,-OH,-SH,-COOH,-C(=O)NH2,-C(=O)NHCH3,-C(=O)N(CH3)2-C (═ O) -alkyl, -C (═ O) -alkoxy, -NHS (═ O)2-alkyl, -N (alkyl) S (═ O)2-alkyl, -S (═ O)2Alkyl, alkoxy, alkylthio, alkylamino, alkenyl, alkynyl, haloalkyl, haloalkoxy, hydroxy-substituted alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkyl-alkylene, heterocyclyl-alkylene, aryl-alkylene, heteroaryl-alkylene and the like.
In the various parts of this specification, substituents of the disclosed compounds are disclosed in terms of group type or range. It is specifically intended that the invention includes each and every independent subcombination of the various members of these groups and ranges. For example, the term "C1-C6Alkyl "means in particular independently disclosed methyl, ethyl, C3Alkyl radical, C4Alkyl radical, C5Alkyl and C6An alkyl group.
In each of the parts of the invention, linking substituents are described. Where the structure clearly requires a linking group, the markush variables listed for that group are understood to be linking groups. For example, if the structure requires a linking group and the markush group definition for the variable recites "alkyl" or "aryl," it is understood that the "alkyl" or "aryl" represents an attached alkylene group or arylene group, respectively.
The terms "halogen" and "halo" are used interchangeably herein to refer to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).
The term "alkyl" or "alkyl group" as used herein, denotes a saturated, straight or branched chain, monovalent hydrocarbon group containing 1 to 20 carbon atoms, wherein the alkyl group may be optionally substituted with one or more substituents as described herein. In some embodiments, the alkyl group contains 1 to 6 carbon atoms; in other embodiments, the alkyl group contains 1 to 4 carbon atoms; in still other embodiments, the alkyl group contains 1 to 3 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl (Me, -CH)3) Ethyl group (Et, -CH)2CH3) N-propyl (n-Pr, -CH)2CH2CH3) Isopropyl group (i-Pr, -CH (CH)3)2) N-butyl (n-Bu, -CH)2CH2CH2CH3) Isobutyl (i-Bu, -CH)2CH(CH3)2(2-methylpropyl)), sec-butyl (s-Bu, -CH (CH)3)CH2CH3(1-methylpropyl)), tert-butyl (t-Bu, -C (CH)3)3) And so on.
The term "alkylene" refers to a saturated divalent hydrocarbon radical resulting from the removal of two hydrogen atoms from a saturated straight or branched chain hydrocarbon. Unless otherwise specified, the alkylene group contains 1 to 10 carbon atoms. In some embodiments, the alkylene group contains 1 to 6 carbon atoms; in other embodiments, the alkylene group contains 1 to 4 carbon atoms; in still other embodiments, the alkylene group contains 1 to 2 carbon atoms. Examples include, but are not limited to, methylene (-CH)2-) ethylene (-CH2CH2-) propylene (-CH)2CH2CH2-) isopropylidene (-CH (CH)3)CH2-) and the like. The alkylene group is optionally substituted with one or more substituents described herein.
The term "alkenyl" denotes a straight or branched chain monovalent hydrocarbon radical containing 2 to 12 carbon atoms, wherein there is at least one site of unsaturation, i.e. one carbon-carbon sp2A double bond, wherein the alkenyl group may be optionally substituted with one or more substituents described herein, including the positioning of "cis" and "trans", or the positioning of "E" and "Z". In one embodiment, the alkenyl group contains 2 to 8 carbon atoms; in another embodiment, the alkenyl group contains 2 to 6 carbon atoms; in yet another embodiment, the alkenyl group contains 2 to 4 carbon atoms. Examples of alkenyl groups include, but are not limited to, vinyl (-CH ═ CH)2) Allyl (-CH)2CH=CH2) 1-propenyl (i.e., propenyl, -CH ═ CH-CH)3) And so on.
The term "alkynyl" denotes a straight or branched chain monovalent hydrocarbon radical containing 2 to 12 carbon atoms, wherein there is at least one site of unsaturation, i.e. one carbon-carbon sp triple bond, wherein the alkynyl radical isMay be optionally substituted with one or more substituents as described herein. In one embodiment, alkynyl groups contain 2-8 carbon atoms; in another embodiment, alkynyl groups contain 2-6 carbon atoms; in yet another embodiment, alkynyl groups contain 2-4 carbon atoms. Examples of alkynyl groups include, but are not limited to, ethynyl (-C.ident.CH), propargyl (-CH)2C.ident.CH), 1-propynyl (i.e., propynyl, -C.ident.C-CH)3) And so on.
The term "alkoxy" means an alkyl group attached to the rest of the molecule through an oxygen atom, wherein the alkyl group has the meaning as described herein. Unless otherwise specified, the alkoxy group contains 1 to 12 carbon atoms. In some embodiments, alkoxy groups contain 1 to 6 carbon atoms; in other embodiments, the alkoxy group contains 1 to 4 carbon atoms; in still other embodiments, alkoxy groups contain 1-3 carbon atoms. The alkoxy group may be optionally substituted with one or more substituents described herein. Examples of alkoxy groups include, but are not limited to, methoxy (MeO, -OCH)3) Ethoxy (EtO, -OCH)2CH3) 1-propoxy (n-propoxy, n-PrO, n-propoxy, -OCH2CH2CH3) 2-propoxy (isopropoxy, i-PrO, i-propoxy, -OCH (CH)3)2) 1-butoxy (n-BuO, n-butoxy, -OCH)2CH2CH2CH3) 2-methyl-l-propoxy (i-BuO, i-butoxy, -OCH)2CH(CH3)2) 2-butoxy (s-BuO, s-butoxy, -OCH (CH)3)CH2CH3) 2-methyl-2-propoxy (t-BuO, t-butoxy, -OC (CH)3)3) And so on.
The term "alkylthio" means an alkyl group attached to the rest of the molecule through a sulfur atom, wherein the alkyl group has the meaning as described herein. Unless otherwise specified, the alkylthio group contains 1 to 12 carbon atoms. In some embodiments, the alkylthio group contains 1 to 6 carbon atoms; in other embodiments, the alkylthio group contains 1 to 4 carbon atoms; in yet another aspectIn some embodiments, the alkylthio group contains 1 to 3 carbon atoms. The alkylthio group may be optionally substituted with one or more substituents described herein. Examples of alkylthio groups include, but are not limited to, methylthio (MeS, -SCH)3) Ethylthio (EtS, -SCH)2CH3) And so on.
The term "alkylamino" or "alkylamino" denotes an amino group independently substituted with one or two alkyl groups, respectively, including "N-alkylamino" and "N, N-dialkylamino" wherein the alkyl groups have the meaning as described herein. Suitable alkylamino groups can be monoalkylamino or dialkylamino, and such examples include, but are not limited to, N-methylamino (methylamino), N-ethylamino (ethylamino), N-dimethylamino (dimethylamino), N-diethylamino (diethylamino), and the like. The alkylamino group is optionally substituted with one or more substituents described herein.
The term "hydroxy-substituted alkyl" means that the alkyl group is substituted with one or more hydroxy groups (-OH), wherein the alkyl group has the meaning as described herein. Unless otherwise specified, the hydroxy-substituted alkyl group contains 1 to 12 carbon atoms. In some embodiments, the hydroxy-substituted alkyl group contains 1 to 6 carbon atoms, e.g., hydroxy-substituted C1-C6An alkyl group; in other embodiments, the hydroxy-substituted alkyl group contains 1 to 4 carbon atoms, e.g., hydroxy-substituted C1-C4An alkyl group; in still other embodiments, the hydroxy-substituted alkyl group contains 1 to 3 carbon atoms, e.g., hydroxy-substituted C1-C3An alkyl group. Examples include, but are not limited to, hydroxymethyl, hydroxyethyl (e.g., 2-hydroxyethyl), 2-hydroxy-1-propyl, 3-hydroxy-1-propyl, 2, 3-dihydroxypropyl, and the like.
The term "cyano-substituted alkyl" denotes an alkyl group substituted with one or more cyano (-CN) groups, wherein the alkyl group has the meaning as described herein. Unless otherwise specified, the cyano-substituted alkyl group contains 1 to 12 carbon atoms. In some embodiments, cyano-substituted alkanesThe radical containing 1 to 6 carbon atoms, e.g. cyano-substituted C1-C6An alkyl group; in other embodiments, the cyano-substituted alkyl group contains 1 to 4 carbon atoms, e.g., cyano-substituted C1-C4An alkyl group; in still other embodiments, the cyano-substituted alkyl group contains 1 to 3 carbon atoms, e.g., cyano-substituted C1-C3An alkyl group. Examples include, but are not limited to, cyanomethyl (-CH)2CN), cyanoethyl (e.g. 2-cyanoethyl, -CH)2CH2CN), 2-cyano-1-propyl (-CH)2CH(CN)CH3) 3-cyano-1-propyl (-CH)2CH2CH2CN), 2, 3-dicyanopropyl group (-CH)2CH(CN)CH2CN), and the like.
The term "amino-substituted alkyl" denotes an alkyl group substituted with one or more amino groups (-NH)2) Wherein the alkyl group has the meaning as described herein. Unless otherwise specified, the amino-substituted alkyl group contains 1 to 12 carbon atoms. In some embodiments, the amino-substituted alkyl group contains 1 to 6 carbon atoms, e.g., amino-substituted C1-C6An alkyl group; in other embodiments, the amino-substituted alkyl group contains 1 to 4 carbon atoms, e.g., amino-substituted C1-C4An alkyl group; in still other embodiments, the amino-substituted alkyl group contains 1 to 3 carbon atoms, e.g., amino-substituted C1-C3An alkyl group. Examples include, but are not limited to, aminomethyl (-CH)2NH2) Aminoethyl (e.g. 2-aminoethyl, -CH)2CH2NH2) 2-amino-1-propyl (-CH)2CH(NH2)CH3) 3-amino-1-propyl (-CH)2CH2CH2NH2) 2, 3-diaminopropyl (-CH)2CH(NH2)CH2NH2) And so on.
The term "haloalkyl" or "haloalkoxy" denotes an alkyl or alkoxy group substituted with one or more halogen atoms, wherein the alkyl and alkoxy groups have the meaning as described herein, whichLike examples include, but are not limited to, -CHF2、-CF3、-CHFCH2F、-CF2CHF2、 -CH2CHF2、-CH2CF3、-CH2CF2CHF2、-OCHF2、-OCF3、-OCHFCH2F、-OCF2CHF2、-OCH2CHF2、-OCH2CF3、 -OCH2CF2CHF2And the like. In some embodiments, C1-C6The haloalkyl group containing a fluorine-substituted C1-C6An alkyl group; in other embodiments, C1-C4The haloalkyl group containing a fluorine-substituted C1-C4An alkyl group; in still other embodiments, C1-C2The haloalkyl group containing a fluorine-substituted C1-C2An alkyl group.
The term "cycloalkyl" denotes a saturated monocyclic, bicyclic or tricyclic ring system containing from 3 to 12 ring carbon atoms. In some embodiments, cycloalkyl groups contain 3 to 10 ring carbon atoms, e.g., C3-10A cycloalkyl group; in other embodiments, cycloalkyl groups contain 3 to 8 ring carbon atoms, e.g., C3-8A cycloalkyl group; in still other embodiments, cycloalkyl groups contain 3-6 ring carbon atoms, e.g., C3-6A cycloalkyl group. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. Wherein, as described in the present invention, C3-8Cycloalkyl radicals including C3-6A cycloalkyl group; said C3-6Cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The cycloalkyl group may be optionally substituted with one or more substituents described herein.
The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic, bicyclic, or tricyclic ring system containing 3 to 12 ring atoms, wherein at least one ring atom is selected from the group consisting of nitrogen, sulfur, and oxygen atoms; wherein the heterocyclic group is non-aromatic and does not contain any aromatic ring. Unless otherwise specified, heterocyclyl may be carbon-or nitrogen-based, and-CH2The radical-may optionally be replaced by-C (═ O) -groupAnd (4) generation. The sulfur atom of the ring may optionally be oxidized to the S-oxide. The nitrogen atoms of the ring may optionally be oxidized to the N-oxide. The term "heterocyclyl" may be used interchangeably with the term "heterocycle". As described herein, the heterocyclyl group may consist of 3 to 8 atoms or 3 to 6 atoms, optionally selected from C, N, O or S and at least one atom being N, O or S; wherein the heterocyclic group consisting of 3 to 8 atoms includes a heterocyclic group consisting of 3 to 6 atoms; the heterocyclic group consisting of 3 to 6 atoms includes a heterocyclic group consisting of 3 to 5 atoms. Specifically, the heterocyclic group consisting of 3 to 6 atoms includes, but is not limited to, ethylene oxide, aziridinyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiazolidinyl, pyrazolidinyl, pyrazolinyl, oxazolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, and the like. The heterocyclyl group may be optionally substituted with one or more substituents described herein.
The term "aryl" denotes a monocyclic, bicyclic and tricyclic carbocyclic ring system containing 6 to 14 ring atoms, or 6 to 12 ring atoms, or 6 to 10 ring atoms, wherein at least one ring is aromatic and has one or more attachment points to the rest of the molecule. The term "aryl" may be used interchangeably with the terms "aromatic ring" or "aromatic ring". Examples of the aryl group may include phenyl, indenyl, 2, 3-dihydro-1H-indenyl, naphthyl and anthryl. The aryl group may be optionally substituted with one or more substituents described herein. Unless otherwise stated, the group "C6-10Aryl "represents an aryl group containing from 6 to 10 ring carbon atoms.
The term "heteroaryl" denotes monocyclic, bicyclic and tricyclic ring systems containing 5 to 12 ring atoms, or 5 to 10 ring atoms, or 5 to 6 ring atoms, wherein at least one ring is aromatic and at least one ring contains 1,2,3 or 4 ring heteroatoms selected from nitrogen, oxygen, sulfur, and wherein the heteroaryl has one or more attachment points to the rest of the molecule. when-CH is present in the heteroaryl group2When it is a group, -CH2-the group may optionally be replaced by-C (═ O) -. Unless otherwise statedThe heteroaryl group may be attached to the rest of the molecule (e.g. the main structure in the general formula) via any reasonable site which may be C or N. The term "heteroaryl" may be used interchangeably with the terms "heteroaromatic ring" or "heteroaromatic compound". The heteroaryl group may be optionally substituted with one or more substituents described herein. In some embodiments, heteroaryl is 5-10 atom consisting of heteroaryl, meaning that heteroaryl contains 1-9 ring carbon atoms and 1,2,3, or 4 ring heteroatoms selected from O, S and N; in other embodiments, heteroaryl is 5-6 atom heteroaryl, meaning that heteroaryl contains 1-5 ring carbon atoms and 1,2,3, or 4 ring heteroatoms selected from O, S and N; examples of heteroaryl groups consisting of 5 to 6 atoms include, but are not limited to, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, thiazolyl, triazolyl, tetrazolyl, and the like.
The term "j-k atoms" means that the cyclic group consists of j-k ring atoms including carbon atoms and/or heteroatoms such as O, N, S, P; j and k are each independently any non-zero natural number, and k > j; the term "j-k" includes j, k and any natural number therebetween. For example, "3-8 atoms", "3-6 atoms", "5-10 atoms", or "5-6 atoms" means that the cyclic group consists of 3-8, 3-6, 5-10, or 5-6 ring atoms, including carbon atoms and/or heteroatoms such as O, N, S, P.
The terms "cycloalkylalkylene", "heterocyclylalkylene", "arylalkylene", "heteroarylalkylene" mean that the cycloalkyl, heterocyclyl, aryl or heteroaryl groups are each independently attached to the rest of the molecule through an alkylene group, wherein the cycloalkyl, heterocyclyl, aryl, heteroaryl and alkylene groups all have the meaning described herein. For example, examples of arylalkylene groups include, but are not limited to, phenylmethylene, phenylethylene, phenylpropylene, and the like. The cycloalkylalkylene, heterocyclylalkylene, arylalkylene, heteroarylalkylene are each independently optionally substituted with one or more substituents described herein.
The term "prodrug", as used herein, represents a compound that is converted in vivo to a compound of formula (I) or formula (II). Such conversion is effected by hydrolysis of the prodrug in the blood or by enzymatic conversion to the parent structure in the blood or tissue. The prodrug compound of the invention can be ester, and in the prior invention, the ester can be used as the prodrug and comprises phenyl ester and aliphatic (C)1-24) Esters, acyloxymethyl esters, carbonates, carbamates and amino acid esters. For example, a compound of the present invention contains a hydroxy group, i.e., it can be acylated to provide the compound in prodrug form. Other prodrug forms include phosphate esters, such as those obtained by phosphorylation of a hydroxyl group on the parent.
"metabolite" refers to the product of a particular compound or salt thereof obtained by metabolism in vivo. Metabolites of a compound can be identified by techniques well known in the art, and its activity can be characterized by assay methods as described herein. Such products may be obtained by administering the compound by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, defatting, enzymatic cleavage, and the like. Accordingly, the present invention includes metabolites of compounds, including metabolites produced by contacting a compound of the present invention with a mammal for a sufficient period of time.
As used herein, "pharmaceutically acceptable salts" refer to organic and inorganic salts of the compounds of the present invention. Pharmaceutically acceptable salts are well known in the art, as are: berge et al, description of the scientific acceptable salts in detail in J. Pharmaceutical Sciences,1977,66:1-19. Pharmaceutically acceptable non-toxic acid salts include, but are not limited to, inorganic acid salts formed by reaction with amino groups such as hydrochloride, hydrobromide, phosphate, sulfate, perchlorate, and organic acid salts such as acetate, oxalate, maleate, tartrate, citrate,succinate, malonate, or by other methods described in the literature, such as ion exchange. The present invention also contemplates quaternary ammonium salts formed from compounds containing groups of N. Water-soluble or oil-soluble or dispersion products can be obtained by quaternization. Pharmaceutically acceptable salts further include suitable, non-toxic ammonium, quaternary ammonium salts and amine cations resistant to formation of counterions, such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, C1-C8Sulfonates and aromatic sulfonates.
"solvate" of the present invention refers to an association of one or more solvent molecules with a compound of the present invention. Solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, ethanolamine, or mixtures thereof. The term "hydrate" refers to an association of solvent molecules that is water.
When the solvent is water, the term "hydrate" may be used. In one embodiment, a molecule of a compound of the present invention may be associated with a molecule of water, such as a monohydrate; in another embodiment, one molecule of the compound of the present invention may be associated with more than one molecule of water, such as a dihydrate; in yet another embodiment, one molecule of the compound of the present invention may be associated with less than one molecule of water, such as a hemihydrate. It should be noted that the hydrates of the present invention retain the biological effectiveness of the compound in its non-hydrated form.
The term "treating" or "treatment" as used herein refers, in some embodiments, to ameliorating a disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one clinical symptom thereof). In other embodiments, "treating" or "treatment" refers to moderating or improving at least one physical parameter, including physical parameters that may not be perceived by the patient. In other embodiments, "treating" or "treatment" refers to modulating the disease or disorder, either physically (e.g., stabilizing a perceptible symptom) or physiologically (e.g., stabilizing a parameter of the body), or both. In other embodiments, "treating" or "treatment" refers to preventing or delaying the onset, occurrence, or worsening of a disease or disorder.
The term "prevent" or "prevention" refers to a reduction in the risk of acquiring a disease or disorder (i.e., arresting the development of at least one clinical symptom of a disease in a subject that may be facing or predisposed to facing such a disease, but who has not yet experienced or exhibited symptoms of the disease).
The term "therapeutically effective amount" means an amount of a compound that, when administered to a subject to treat a disease, is sufficient to effect treatment of the disease. The "therapeutically effective amount" may vary with the compound, the disease and the severity, as well as the condition, age, weight, sex, etc., of the subject to be treated.
Unless otherwise indicated, all suitable isotopic variations, stereoisomers, tautomers, solvates, metabolites, pharmaceutically acceptable salts and prodrugs thereof, of the compounds of the present invention are encompassed within the scope of the present invention.
In the structures disclosed herein, when the stereochemistry of any particular chiral atom is not specified, then all stereoisomers of that structure are contemplated as within this invention and are included as disclosed compounds in this invention. When stereochemistry is indicated by a solid wedge (solid wedge) or dashed line representing a particular configuration, then the stereoisomers of the structure are so well-defined and defined.
Nitroxides of the compounds of the present invention are also included within the scope of the present invention. The nitroxides of the compounds of the present invention may be prepared by oxidation of the corresponding nitrogen-containing basic species using a common oxidizing agent (e.g. hydrogen peroxide) in the presence of an acid such as acetic acid at elevated temperature, or by reaction with a peracid in a suitable solvent, for example peracetic acid in dichloromethane, ethyl acetate or methyl acetate, or 3-chloroperoxybenzoic acid in chloroform or dichloromethane.
The compounds of formula (I) or formula (II) may be present in the form of a salt. In some embodiments, the salt refers to a pharmaceutically acceptable salt. The term "pharmaceutically acceptable" means that the substance or composition must be chemically and/or toxicologically compatible with the other ingredients comprising the formulation and/or the mammal being treated therewith. In other embodiments, the salt need not be a pharmaceutically acceptable salt, and may be an intermediate useful in the preparation and/or purification of a compound of formula (I) or formula (II) and/or in the isolation of an enantiomer of a compound of formula (I) or formula (II).
Any formulae given herein are also intended to represent the non-isotopically enriched forms as well as the isotopically enriched forms of these compounds. Isotopically enriched compounds have the structure depicted by the formulae given herein, except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Exemplary isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as2H、3H、11C、13C、14C、15N、17O、18O、18F、31P、32P、35S、36Cl and125I。
in another aspect, the invention relates to intermediates for the preparation of compounds of formula (I) or formula (II).
Pharmaceutical compositions, formulations and administration of the compounds of the invention
The invention provides a pharmaceutical composition, which comprises a compound shown as a formula (I) or a formula (II) or an individual stereoisomer, a racemic or non-racemic mixture of isomers or a pharmaceutically acceptable salt or solvate thereof. In some embodiments of the invention, the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier, adjuvant or vehicle, and optionally, other therapeutic and/or prophylactic ingredients.
Suitable carriers, adjuvants and excipients are well known to those skilled in the art and are described in detail, for example, in Ansel h.c.et al, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems (2004) Lippincott, Williams & Wilkins, philidelphia; gennaro a.r.et al, Remington: the Science and Practice of Pharmacy (2000) Lippincott, Williams & Wilkins, Philadelphia; and Rowe R.C., Handbook of Pharmaceutical Excipients (2005) Pharmaceutical Press, Chicago.
It will also be appreciated that certain compounds of the invention may be present in free form or, if appropriate, in the form of a pharmaceutically acceptable derivative thereof, when used in therapy. Some non-limiting embodiments of pharmaceutically acceptable derivatives include pharmaceutically acceptable prodrugs, salts, esters, salts of such esters, or any additional adduct or derivative that upon administration to a patient in need thereof provides, directly or indirectly, a compound of the present invention or a metabolite or residue thereof.
Suitable pharmaceutically acceptable excipients will vary depending on the particular dosage form selected. In addition, pharmaceutically acceptable excipients may be selected for their specific function in the composition. Suitable pharmaceutically acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, taste masking agents, colorants, anti-caking agents, humectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants and buffers. The skilled artisan will recognize that certain pharmaceutically acceptable excipients may provide more than one function, and provide alternative functions, depending on how many such excipients are present in the formulation and which other excipients are present in the formulation.
The pharmaceutical compositions disclosed herein are prepared using techniques and methods known to those skilled in the art. Some commonly used methods in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing Company).
Thus, in another aspect, the invention relates to a process for preparing a pharmaceutical composition comprising a compound of the present disclosure and a pharmaceutically acceptable excipient, carrier, adjuvant, vehicle or combination thereof, which process comprises admixing the ingredients. Pharmaceutical compositions comprising the disclosed compounds may be prepared by mixing, for example, at ambient temperature and atmospheric pressure.
The compounds disclosed herein are generally formulated in a dosage form suitable for administration to a patient by a desired route. For example, dosage forms include those suitable for the following routes of administration: (1) oral administration, such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets and cachets; (2) parenteral administration, such as sterile solutions, suspensions, and reconstituted powders; (3) transdermal administration, such as transdermal patches; (4) rectal administration, e.g., suppositories; (5) inhalation, such as aerosols, solutions, and dry powders; and (6) topical administration, such as creams, ointments, lotions, solutions, pastes, sprays, foams and gels.
In some embodiments, the compounds disclosed herein can be formulated in oral dosage forms. In other embodiments, the compounds disclosed herein may be formulated in an inhalation dosage form. In other embodiments, the compounds disclosed herein can be formulated for nasal administration. In still other embodiments, the compounds disclosed herein can be formulated for transdermal administration. In still other embodiments, the compounds disclosed herein may be formulated for topical administration.
The pharmaceutical compositions provided by the present invention may be provided as compressed tablets, milled tablets, chewable lozenges, fast-dissolving tablets, double-compressed tablets, enteric-coated tablets, sugar-coated or film-coated tablets.
The pharmaceutical composition provided by the present invention may be provided in soft or hard capsules, which may be prepared from gelatin, methylcellulose, starch or calcium alginate.
The pharmaceutical compositions provided by the present invention may be administered parenterally by injection, infusion or implantation for local or systemic administration. Parenteral administration as used herein includes intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial and subcutaneous administration.
The pharmaceutical compositions provided herein can be formulated in any dosage form suitable for parenteral administration, including solutions, suspensions, emulsions, micelles, liposomes, microspheres, nanosystems and solid forms suitable for solution or suspension in a liquid prior to injection. Such dosage forms may be prepared according to conventional methods known to those skilled in The art of pharmaceutical Science (see Remington: The Science and Practice of Pharmacy, supra).
In another aspect, the disclosed pharmaceutical compositions may be formulated in any dosage form suitable for administration to a patient by inhalation, such as a dry powder, aerosol, suspension, or solution composition.
Pharmaceutical compositions suitable for transdermal administration may be prepared as discrete patches intended to remain in intimate contact with the epidermis of the patient for an extended period of time. For example, the active ingredient may be delivered from a patch agent by iontophoresis, as generally described in Pharmaceutical Research,3(6),318 (1986).
Pharmaceutical compositions suitable for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
Use of the Compounds and pharmaceutical compositions of the invention
The compounds and pharmaceutical compositions provided by the present invention have excellent GnRH antagonistic activity and low toxicity (e.g., acute toxicity, chronic toxicity, genetic toxicity, reproductive toxicity, cardiotoxin, drug interactions and carcinogenicity). Also, the compound or the pharmaceutical composition is excellent in oral absorbability, action sustainability, stability and pharmacokinetics. Furthermore, the compounds or pharmaceutical compositions are less affected by plasma components. Therefore, the compound or the pharmaceutical composition of the present invention can be safely used in mammals (e.g., human, monkey, cow, horse, dog, cat, rabbit, rat, mouse, etc.) to prevent and/or treat diseases depending on male or female hormones, diseases caused by excess of these hormones, etc. by controlling plasma sex hormone concentration using GnRH receptor antagonism to inhibit gonadotropin secretion.
Specifically, the compound or the pharmaceutical composition of the present invention is suitable for the prevention and/or treatment of sex hormone-dependent cancer (e.g., prostate cancer, uterine cancer, breast cancer, pituitary tumor, etc.), bone metastasis of sex hormone-dependent cancer, prostatic hypertrophy, uterine myoma, endometriosis, uterine fibroid, precocious puberty, amenorrhea, premenstrual syndrome, dysmenorrhea, multiple atrial ovarian syndrome (multilocular ovarian syndrome), polycystic ovarian syndrome, acne, alopecia, alzheimer's disease (alzheimer's disease, senile dementia of the alzheimer's type and a mixed type thereof), and the like. The compounds of the invention are also useful for regulating male and female reproduction (e.g., pregnancy regulators, menstrual cycle regulators, and the like). The compounds or pharmaceutical compositions of the invention may also be used as male or female contraceptives or as female ovulation inducers. Based on the rebound effect after drug withdrawal, the compound or the pharmaceutical composition of the invention can be used for treating infertility. Furthermore, the compounds or pharmaceutical compositions of the present invention can be used as agents for the prevention and/or treatment of hormone-independent and LH-RH sensitive benign or malignant tumors. Furthermore, the compound or the pharmaceutical composition of the present invention can be used as an agent for preventing and/or treating irritable bowel syndrome and preventing postoperative recurrence of sex hormone-dependent cancer (an agent for preventing postoperative recurrence of prostate cancer; an agent for preventing postoperative recurrence of breast cancer or ovarian cancer before or after menopause; particularly an agent for preventing postoperative recurrence of breast cancer or ovarian cancer before menopause).
Furthermore, the compounds or pharmaceutical compositions of the invention are suitable for regulating the estrus of animals, improving the quality of meat and promoting the growth of animals in animal husbandry. The compounds of the present invention are also suitable for fish spawning promoters (fisher spawning promoters).
The compounds or pharmaceutical compositions of the present invention may also be used to inhibit transient increases in plasma testosterone concentrations (flare phenomena) observed when administering GnRH superagonists such as acremolin acetate. The compound of the present invention can be used in combination with a super-agonist such as leuprolide acetate, gonadorelin (gonadorelin), buserelin (buserelin), triptorelin (triptorelin), goserelin (goserelin), nalfrelin (nafarelin), histrelin (histrelin), deslorelin (deslorelin), mirerelin (meterelin) and goserelin (lecirelin). Especially preferred is leuprolide acetate.
It may also be particularly advantageous to use the compounds or pharmaceutical compositions of the invention in combination with at least one substance selected from the group consisting of steroidal or non-steroidal antiandrogenic agents or antiestrogenic agents, chemotherapeutic agents, GnRH antagonist peptides, alpha-reductase inhibitors, alpha-receptor inhibitors, aromatase inhibitors, 17 beta-hydroxysteroid dehydrogenase inhibitors, adrenoandrogen production inhibitors, kinase inhibitors, hormone therapy agents and agents inhibiting cell growth factors or their receptors.
The above-mentioned "chemotherapeutic agent" includes ifosfamide (ifosfamide), doxorubicin (adriamycin), pellomycin (polyplomycin), cisplatin (cissplatin), cyclophosphamide (cyclophosphamide), 5-FU, UFT, methotrexate (methotrexate), mitomycin C (mitomycin C), mitoxantrone (mitoxantrone), and the like. The above-mentioned "GnRH antagonistic peptide" includes non-oral GnRH antagonistic peptides such as cetrorelix (cetrorelix), ganirelix (ganirelix), abarelix (abarelix), and the like.
In addition to being beneficial for human therapy, the compounds and pharmaceutical compositions of the present invention may also find application in veterinary therapy for pets, animals of the introduced species and mammals in farm animals. Examples of other animals include horses, dogs, and cats. Herein, the compound of the present invention includes pharmaceutically acceptable derivatives thereof.
In some embodiments, a disclosed compound or a pharmaceutical composition comprising a disclosed compound may be administered once or several times at different time intervals over a specified period of time according to a dosing regimen. The compounds disclosed herein may be administered simultaneously, or before or after, one or more other therapeutic agents. The compounds of the invention may be administered separately from the other therapeutic agents, by the same or different routes of administration, or in the same pharmaceutical composition.
General synthetic procedure
To illustrate the invention, the following examples are set forth. It is to be understood that the invention is not limited to these embodiments, but is provided as a means of practicing the invention.
In general, the compounds of the invention may be prepared by the methods described herein, wherein the substituents are as defined in formula (I) or formula (II), unless otherwise indicated. The following reaction schemes and examples serve to further illustrate the context of the invention.
Those skilled in the art will recognize that: the chemical reactions described herein may be used to suitably prepare a number of other compounds of the invention, and other methods for preparing the compounds of the invention are considered to be within the scope of the invention. For example, the synthesis of those non-exemplified compounds according to the present invention can be successfully accomplished by those skilled in the art by modification, such as appropriate protection of interfering groups, by the use of other known reagents in addition to those described herein, or by some routine modification of reaction conditions. In addition, the reactions disclosed herein or known reaction conditions are also recognized as being applicable to the preparation of other compounds of the present invention.
The examples described below, unless otherwise indicated, are all temperatures set forth in degrees Celsius. Reagents were purchased from commercial suppliers such as Aldrich Chemical Company, Arco Chemical Company and Alfa Chemical Company and were used without further purification unless otherwise indicated. General reagents were purchased from Shantou Wen Long chemical reagent factory, Guangdong Guanghua chemical reagent factory, Guangzhou chemical reagent factory, Tianjin Haojian Yunyu chemical Co., Ltd, Tianjin Shucheng chemical reagent factory, Wuhan Xin Huayuan scientific and technological development Co., Ltd, Qingdao Tenglong chemical reagent Co., Ltd, and Qingdao Kaolingyi factory.
The anhydrous tetrahydrofuran, dioxane, toluene and ether are obtained through reflux drying of metal sodium. The anhydrous dichloromethane and chloroform are obtained by calcium hydride reflux drying. Ethyl acetate, petroleum ether, N-hexane, N, N-dimethylacetamide and N, N-dimethylformamide were used as they were previously dried over anhydrous sodium sulfate.
The following reactions are generally carried out under positive pressure of nitrogen or argon or by sleeving a dry tube over an anhydrous solvent (unless otherwise indicated), the reaction vial being stoppered with a suitable rubber stopper and the substrate being injected by syringe. The glassware was dried.
The column chromatography is performed using a silica gel column. Silica gel (300 and 400 meshes) was purchased from Qingdao oceanic chemical plants.
1H NMR spectra were recorded using a Bruker 400MHz or 600MHz NMR spectrometer.1H NMR Spectrum in CDC13、DMSO-d6、 CD3OD or acetone-d6TMS (0ppm) or chloroform (7.26ppm) was used as a reference standard for the solvent (in ppm). When multiple peaks occur, the following abbreviations will be used: s (singlets, singlet), d (doublets ), t (triplets, triplet), q (quatets, quartets), m (multiplets ), br (broadended, broad), brs (broadended singlets, broad singlet), dd (doublets ), ddd (doublets, doublets), ddles of doublets), ddt (doublets of doublets, doublets), dt (doublets ), dq (doublets of doublets, doublets), td (triplets of doublets, triplet), tt (triplet of triplets). Coupling constant J, expressed in Hertz (Hz).
The conditions for determining low resolution Mass Spectrometry (MS) data were: agilent 6120 four-stage rod HPLC-M (column model: Zorbax SB-C18, 2.1X 30mm,3.5 micron, 6min, flow rate 0.6 mL/min. mobile phase 5% -95% (CH with 0.1% formic acid)3CN) in (H containing 0.1% formic acid)2O) by electrospray ionization (ESI) at 210nm/254nm, with UV detection.
Pure compounds were detected by UV at 210nm/254nm using Agilent 1260pre-HPLC or Calesep pump 250pre-HPLC (column model: NOVASEP 50/80 mm DAC).
The following acronyms are used throughout the invention:
mmol of DMF N, N-dimethylformamide
CDC13Deuterated chloroform nM, nmol/L nanomole per liter
DMSO dimethyl sulfoxide M, mol/L, mol per liter
DMSO-d6Deuterated dimethyl sulfoxide mg
G of AIBN azobisisobutyronitrile
Kg of NBS N-bromosuccinimide
EA Ethyl acetate mL, mL
DCM Dichloromethane μ L, μ L microliter
Saline normal Saline Pd/C palladium/carbon
min PEG400 polyethylene glycol 400
h hour EDTA-K2Ethylenediaminetetraacetic acid dipotassium salt
Py pyridine RT, RT Room temperature
The following synthetic schemes describe the procedures for preparing the presently disclosed compounds, wherein X and R are as follows, unless otherwise indicated1Having the definitions set out in the present invention.
Synthesis scheme 1
Formula (A), (B) and15) The compound shown can be prepared by the following steps: formula (A), (B) and1) A compound of the formula2) Reacting the cyanoacetic acid ethyl ester to obtain a compound of formula (I)3) A compound shown in the specification; then formula (A), (B), (C)3) The compound is subjected to ring closing under the action of sulfur powder to obtain a compound of the formula (I)4) The compounds shown. Formula (II)(4) Reacting the compound with phenyl chloroformate to obtain a compound of formula (I)5) The compounds shown. Formula (A), (B) and5) A compound of the formula6) The compound shown in the formula (I) is reacted to obtain7) A compound shown in the specification; formula (A), (B) and7) The compound is subjected to ring closure reaction to obtain a compound of the formula (I)8) The compounds shown. Formula (A), (B) and8) A compound of the formula9) Reacting the compound shown in the formula (A) to obtain a compound shown in the formula (B)10) The compounds shown. Formula (A), (B) and10) Brominating the compound shown to obtain a compound shown as a formula (I)11) A compound shown in the specification; formula (II)(11) The compound shown is reacted with dimethylamine hydrochloride to obtain a compound shown as a formula (I)12) A compound shown in the specification; formula (A), (B) and12) Reduction of the nitro group of the compound to give a compound of the formula13) A compound shown in the specification; formula (A), (B) and13) A compound of the formula14) Or formula (A)14’) The compound shown in the formula (I) is reacted to obtain15) The target product shown.
The compounds, pharmaceutical compositions and uses thereof provided by the present invention are further illustrated below in connection with the examples.
Examples
Example Synthesis of 4- (1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -2, 4-dioxo-3- (tetrahydro-2H-pyran-4-yl) -1,2,3, 4-tetrahydrothieno [2,3-d ] pyrimidin-6-yl) phenyl) -3-methoxyurea
Step 1) Synthesis of (E/Z) -2-cyano-3-methyl-4- (4-nitrophenyl) butyl-2-enoic acid ethyl ester
P-nitroacetophenone (5.3g,29.6mmol) and ethyl cyanoacetate (9.64mL,88.8mmol) were added to a 250mL single-neck round-bottom flask, followed by the addition of n-heptanoic acid (4.37mL,29.6mmol), benzylamine (3.6mL,32mmol) and toluene (50mL), followed by reaction for 12 hours at 130 ℃ over a water separator; after completion of the reaction, it was cooled to room temperature, spin-dried under reduced pressure, and purified by column chromatography (petroleum ether/ethyl acetate (v/v) ═ 18/1) to give the title compound as a pale yellow oil (7.24g, 89.2%).
MS(ESI,neg.ion)m/z:273.3[M-H]-.
Step 2) Ethyl 2-amino-4-methyl-5- (4-nitrophenyl)) Synthesis of thiophene-3-carboxylic acid esters
(E/Z) -2-cyano-3-methyl-4- (4-nitrophenyl) butyl-2-enoic acid ethyl ester (7.2g,26.2mmol), sulfur powder (1.68g,52.4mmol) and ethanol (80mL) were added to a 250mL single-neck round-bottom flask, diethylamine (6.8mL,65mmol) was added, the reaction was stirred for 15 minutes, and then transferred to 65 ℃ for further reaction for 3 hours; the reaction was stopped, cooled to room temperature, spin-dried under reduced pressure, and purified by column chromatography (petroleum ether/dichloromethane (v/v) ═ 5/1) to give the title compound as a red-brown solid (5.23g, 65.1%).
MS(ESI,pos.ion)m/z:307.1[M+H]+;
1H NMR(600MHz,CDCl3)δ(ppm)8.22(d,J=8.9Hz,2H),7.48(d,J=8.9Hz,2H),6.27(s,2H),4.33(q,J= 7.1Hz,2H),2.40(s,3H),1.38(t,J=7.1Hz,3H).
Step 3) Synthesis of Ethyl 4-methyl-5- (4-nitrophenyl) -2- ((phenoxycarbonylacyl) amino) thiophene-3-carboxylate
Become into
Ethyl 2-amino-4-methyl-5- (4-nitrophenyl) thiophene-3-carboxylate (10.5g,34.3mmol), pyridine (9.7mL,120 mmol), and methylene chloride (100mL) were added to a 250mL single-neck round-bottom flask at 25 deg.C, phenyl chloroformate (5.2mL,41mmol) was added, and the reaction was allowed to continue stirring for 2 hours; the reaction was stopped, water (50mL) was added, anhydrous sodium sulfate (1.5g) was added, dried, filtered, the filtrate was spin-dried under reduced pressure, and purified by column chromatography (petroleum ether/ethyl acetate (v/v) ═ 30/1) to give the title compound as a yellow solid (12.25g, 83.8%).
MS(ESI,pos.ion)m/z:427.1[M+H]+;
1H NMR(600MHz,CDCl3)δ(ppm)11.04(s,1H),8.27(d,J=8.8Hz,2H),7.55(d,J=8.8Hz,2H),7.41(d,J= 8.3Hz,2H),7.29–7.27(m,1H),7.23(d,J=8.6Hz,2H),4.43(q,J=7.1Hz,2H),2.44(s,3H),1.45(t,J=7.1 Hz,3H).
Step 4) Ethyl 4-methyl-5- (4-nitrophenyl) -2- (3- (tetrahydro-2H-pyran-4-yl) ureido) thiophene-3-
Synthesis of carboxylic acid esters
Ethyl 4-methyl-5- (4-nitrophenyl) -2- ((phenoxycarbonylacyl) amino) thiophene-3-carboxylate (0.64g,1.5mmol) and tetrahydrofuran (25mL) were added to a 100mL single-neck round bottom flask, followed by triethylamine (0.45g,4.4mmol) and tetrahydropyran-4-amine (450mg, 4.4mmol), and the reaction was stirred for an additional 3 hours at 70 deg.C in an oil bath; the reaction was stopped, cooled to room temperature, quenched by addition of water (30mL), extracted with ethyl acetate (40mL), and the organic phase was collected and purified by column chromatography (petroleum ether/ethyl acetate (v/v) ═ 2/1) to give the title compound as a yellow solid (0.58g, 89.1%).
MS(ESI,pos.ion)m/z:434.4[M+H]+;
1H NMR(400MHz,CDCl3)δ(ppm)8.27(d,J=8.6Hz,2H),7.57(d,J=8.6Hz,2H),4.39(q,J=7.1Hz,2H), 4.01(d,J=11.7Hz,2H),3.95(dd,J=7.4,3.8Hz,1H),3.52(t,J=11.0Hz,2H),2.43(s,3H),2.01(d,J=10.7 Hz,2H),1.56(qd,J=11.8,4.4Hz,2H),1.43(t,J=7.1Hz,3H).
Step 5) 5-methyl-6- (4-nitrophenyl) -3- (tetrahydro-2H-pyran-4-yl) thieno [2,3-d]A pyrimidine-2-containing compound having a structure represented by,
synthesis of 4(1H,3H) -dione
Ethyl 4-methyl-5- (4-nitrophenyl) -2- (3- (tetrahydro-2H-pyran-4-yl) ureido) thiophene-3-carboxylate (3.8g,8.8mmol) and methanol (50mL) were added to a 100mL single neck round bottom flask, followed by sodium methoxide (1.2g,22mmol) and the reaction stirred for an additional 5 hours at 70 ℃ in an oil bath; the reaction was stopped, cooled to room temperature, the solvent was removed by rotary drying under reduced pressure, then water (20mL) was added, stirred for 10 min and filtered, and the filter cake was dried at 60 ℃ to give the title compound as a yellow solid (3.1g, 91.2%).
Step 6)1- (2, 6-difluorobenzyl) -5-methyl-6- (4-nitrophenyl) -3- (tetrahydro-2H-pyran-4-yl) thia-ne
Thieno [2,3-d ]]Synthesis of pyrimidine-2, 4(1H,3H) -diones
5-methyl-6- (4-nitrophenyl) -3- (tetrahydro-2H-pyran-4-yl) thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -dione (2.1g, 5.4mmol), potassium iodide (1.7g,10.2mmol), potassium carbonate (1.4g,10.1mmol), and DMF (30mL) were added to a 100mL single-neck round bottom flask at 25 deg.C, followed by 2, 6-difluorobenzyl chloride (1.7g,10mmol), and the reaction was continued for 4 hours; the reaction was stopped, quenched by addition of water (100mL), filtered, and the filter cake solid collected and dried at 60 ℃ to give the title compound as a yellow solid (2.4g, 85.7%).
MS(ESI,pos.ion)m/z:514.2[M+H]+;
1H NMR(400MHz,CDCl3)δ(ppm)8.29(d,J=8.7Hz,2H),7.55(d,J=8.7Hz,2H),7.37–7.30(m,1H),6.94 (t,J=8.1Hz,2H),5.34(s,2H),5.18(ddd,J=12.1,8.3,4.0Hz,1H),4.11(dd,J=11.3,4.1Hz,2H),2.90(qd,J =12.4,4.6Hz,2H),2.60(s,3H),1.60(d,J=12.7Hz,4H).
Step 7)5- (bromomethyl) -1- (2, 6-difluorobenzyl) -6- (4-nitrophenyl) -3- (tetrahydro-2H-pyran-4-
Yl) thieno [2,3-d]Synthesis of pyrimidine-2, 4(1H,3H) -diones
1- (2, 6-difluorobenzyl) -5-methyl-6- (4-nitrophenyl) -3- (tetrahydro-2H-pyran-4-yl) thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -dione (2.4g,4.7mmol), azobisisobutyronitrile (110mg,0.67mmol), N-bromosuccinimide (1.2g, 6.7mmol), and chlorobenzene (50mL) were added to a 100mL single-necked round bottom flask and reacted in an oil bath at 80 ℃ for 7 hours under nitrogen; the reaction was stopped, cooled to room temperature, and a saturated sodium bicarbonate solution (20mL) was added, followed by liquid separation and drying of the organic phase over anhydrous sodium sulfate (1 g); filtration and spin-drying of the filtrate under reduced pressure gave the title compound as a pale yellow solid (2.6g, 95%).
Step 8)1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -6- (4-nitrophenyl) -3- (tetrahydro-
2H-pyran-4-yl) thieno [2,3-d]Synthesis of pyrimidine-2, 4(1H,3H) -diones
5- (bromomethyl) -1- (2, 6-difluorobenzyl) -6- (4-nitrophenyl) -3- (tetrahydro-2H-pyran-4-yl) thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -dione (340mg,0.57mmol), dimethylamine hydrochloride (0.1g,1.2mmol), and DMF (10mL) were added to a 100mL single neck round bottom flask at 25 deg.C, followed by triethylamine (0.3mL,2.14mmol) and the reaction was allowed to stir for an additional 16 hours; the reaction was stopped, water (30mL) was added, ethyl acetate was extracted (40mL), the organic phase was separated, the organic phase was collected, dried under reduced pressure, and purified by column chromatography (dichloromethane/methanol (v/v) ═ 30/1) to give the title compound as a yellow solid (0.25g, 78.3%).
MS(ESI,pos.ion)m/z:557.1[M+H]+;
1H NMR(400MHz,CDCl3)δ(ppm)8.27(d,J=8.6Hz,2H),7.83(d,J=8.7Hz,2H),7.33(dt,J=13.8,6.9Hz, 1H),6.94(t,J=8.1Hz,2H),5.35(s,2H),4.13(dd,J=14.3,7.2Hz,4H),4.08(d,J=4.1Hz,1H),3.78(s,2H), 2.23(s,6H),1.89(brs,2H),1.59(d,J=10.1Hz,2H).
Step 9)6- (4-aminophenyl) -1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -3- (tetrahydro-
2H-pyran-4-yl) thieno [2,3-d]Synthesis of pyrimidine-2, 4(1H,3H) -diones
1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -6- (4-nitrophenyl) -3- (tetrahydro-2H-pyran-4-yl) thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -dione (2.0g,3.6mmol), ethyl hydrogen chloride acetate solution (4mL,2M), and methanol (60mL) were added to a 250mL single neck round bottom flask at 25 ℃ followed by Pd/C (0.6g), and reacted under a hydrogen balloon for 3 hours; the reaction was stopped, the bulk of the solvent was removed by rotary drying under reduced pressure, methanol (10mL) was added, followed by addition of a solid sodium bicarbonate to adjust the pH to 8, and the sample was stirred directly on silica gel and purified by column chromatography (dichloromethane/methanol (v/v) ═ 20/1) to give the title compound as an off-white solid (1.6g, 84.2%).
MS(ESI,pos.ion)m/z:527.2[M+H]+;
1H NMR(400MHz,CDCl3)δ(ppm)8.22(d,J=8.8Hz,2H),7.78(d,J=8.8Hz,2H),7.56(d,J=7.9Hz,1H), 7.45(dd,J=13.1,7.9Hz,1H),7.26–7.19(m,1H),5.50(s,2H),5.17(tt,J=12.0,3.8Hz,1H),4.06(dd,J= 11.3,4.1Hz,2H),3.75(s,2H),3.50(t,J=11.4Hz,2H),2.89(d,J=2.7Hz,2H),2.21(s,6H),1.57(d,J=10.1 Hz,2H).
Step 10)1- (4- (1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -2, 4-dioxo-3- (tetra-amino)
hydro-2H-pyran-4-yl) -1,2,3, 4-tetrahydrothieno [2,3-d]Synthesis of pyrimidin-6-yl) phenyl) -3-methoxyurea
6- (4-aminophenyl) -1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -3- (tetrahydro-2H-pyran-4-yl) thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -dione (0.3g,0.57mmol), phenyl N-methoxycarbamate (0.4g,2.4mmol), and tetrahydrofuran (10mL) were added to a 100mL single neck round bottom flask, followed by triethylamine (0.3mL,2.14mmol), and reacted in an oil bath at 80 ℃ for 6 hours; the reaction was stopped, cooled to room temperature, and then water (50mL) was added, followed by extraction with dichloromethane (70mL), liquid separation, organic phase collection, spin-drying under reduced pressure, and column chromatography purification (dichloromethane/methanol (v/v) ═ 20/1) to give the title compound as a white solid (0.23g, 67.3%).
MS(ESI,pos.ion)m/z:600.3[M+H]+;
1H NMR(600MHz,CDCl3)δ(ppm)7.68(s,1H),7.62(s,1H),7.56(d,J=8.5Hz,2H),7.45(d,J=8.5Hz,2H), 7.31(d,J=6.6Hz,1H),6.91(t,J=8.1Hz,2H),5.32(d,J=5.1Hz,2H),5.21(ddd,J=12.0,8.4,4.0Hz,1H), 4.08(dd,J=11.1,3.9Hz,2H),3.82(s,3H),3.74(s,2H),3.52(t,J=11.4Hz,2H),2.89(qd,J=12.3,4.4Hz, 2H),2.18(s,6H),1.60(d,J=10.3Hz,2H).
Example Synthesis of 21- (4- (1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -2, 4-dioxo-3- (tetrahydro-2H-pyran-4-yl) -1,2,3, 4-tetrahydrothieno [2,3-d ] pyrimidin-6-yl) phenyl) -3-ethylurea
The title compound was prepared as described in example 1, step 10 by reacting 6- (4-aminophenyl) -1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -3- (tetrahydro-2H-pyran-4-yl) thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -dione (0.3g,0.57mmol), ethyl isocyanate (0.2g,2.8mmol), triethylamine (0.4mL,2.9mmol) in tetrahydrofuran (10mL) and purifying the crude product by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 20/1) to give the title compound as a white solid (257mg, 75.5%).
MS(ESI,pos.ion)m/z:598.2[M+H]+;
1H NMR(400MHz,CDCl3)δ(ppm)7.45(s,1H),7.43(s,2H),7.35(d,J=8.4Hz,2H),6.89(t,J=8.1Hz,2H), 5.30(d,J=8.3Hz,2H),5.20(t,J=11.8Hz,1H),4.12–4.02(m,2H),3.73(s,2H),3.47(t,J=11.5Hz,2H), 3.31–3.21(m,2H),2.88(tt,J=12.2,6.1Hz,2H),2.17(s,6H),1.58(d,J=11.0Hz,2H),1.11(t,J=7.2Hz, 3H).
Example Synthesis of 31- (4- (1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -2, 4-dioxo-3- (tetrahydro-2H-pyran-4-yl) -1,2,3, 4-tetrahydrothieno [2,3-d ] pyrimidin-6-yl) phenyl) -3-cyclopropylurea
This step the title compound was prepared as described in example 1, step 10, i.e. 6- (4-aminophenyl) -1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -3- (tetrahydro-2H-pyran-4-yl) thieno [2,3-d]Pyrimidine-2, 4(1H,3H) -dione (0.3g,0.57mmol), phenyl N-cyclopropylcarbamate (0.2g,1.12mmol), triethylamine (0.4mL,2.9mmol) were reacted in tetrahydrofuran (10mL), and the crude product was isolated and purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 15/1) to give the title compound as a white solid (0.14g, 40.3%). MS (ESI, pos.ion) M/z 610.1[ M + H ]]+;
1H NMR(400MHz,CDCl3)δ(ppm)7.87(s,1H),7.52(d,J=8.4Hz,2H),7.32(d,J=8.3Hz,2H),6.90(t,J= 8.1Hz,2H),5.30(s,2H),5.19(t,J=12.0Hz,1H),4.06(dd,J=10.9,3.5Hz,2H),3.84(s,2H),3.48(dd,J= 13.1,9.7Hz,2H),3.04(dd,J=14.5,7.3Hz,1H),2.84(dd,J=12.2,4.1Hz,2H),2.25(s,6H),1.59(d,J=10.8 Hz,2H),0.76(d,J=5.6Hz,2H),0.57(brs,2H).
Example Synthesis of 4- (1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -3- (1, 1-dioxotetrahydro-2H-thiopyran-4-yl) -2, 4-dioxo-1, 2,3, 4-tetrahydrothieno [2,3-d ] pyrimidin-6-yl) phenyl) -3-methoxyurea
Step 1) Ethyl 2- (3- (1, 1-dioxotetrahydro-2H-thiopyran-4-yl) ureido) -4-methyl-5- (4-nitro-n-oxide
Synthesis of phenyl) thiophene-3-carboxylic acid esters
This step was prepared by the method described in example 1, step 4, reacting ethyl 4-methyl-5- (4-nitrophenyl) -2- ((phenoxycarbonyl) amino) thiophene-3-carboxylate (0.85g,1.99mmol), 4-aminotetrahydro-2H-thiopyran 1, 1-dioxide (0.45g,2.99mmol), triethylamine (0.83mL,5.98mmol) in DMF (10mL) and drying to give the title compound as a pale yellow solid (0.8g, 83.3%).
MS(ESI,pos.ion)m/z:480.4[M-H]-;
1H NMR(400MHz,CDCl3)δ(ppm)10.87(s,1H),8.28(d,J=8.6Hz,2H),7.56(d,J=8.6Hz,2H),5.47(d,J= 7.4Hz,1H),4.39(q,J=7.1Hz,2H),4.10–4.01(m,1H),3.18(d,J=4.6Hz,4H),2.43(s,5H),2.28–2.17(m, 2H),1.44(t,J=7.1Hz,3H).
Step 2)3- (1, 1-dioxotetrahydro-2H-thiopyran-4-yl) -5-methyl-6- (4-nitrophenyl) thieno
[2,3-d]Synthesis of pyrimidine-2, 4(1H,3H) -diones
This step was prepared by the method described in reference to example 1, step 5, i.e., ethyl 2- (3- (1, 1-dioxotetrahydro-2H-thiopyran-4-yl) ureido) -4-methyl-5- (4-nitrophenyl) thiophene-3-carboxylate (1.0g,2.08mmol) and sodium methoxide (0.35g,6.23 mmol) were reacted in methanol (20mL) and dried to give the title compound as a pale yellow solid (0.86g, 95.1%).
MS(ESI,pos.ion)m/z:435.9[M+H]+;
1H NMR(400MHz,DMSO-d6)δ(ppm)12.34(s,1H),8.30(d,J=8.7Hz,2H),7.74(d,J=8.7Hz,2H),5.11(s, 1H),3.08(d,J=12.1Hz,4H),2.52(d,J=2.8Hz,3H),2.44(s,2H),1.92(d,J=11.9Hz,2H).
Step 3)1- (2, 6-difluorobenzyl) -3- (1, 1-dioxotetrahydro-2H-thiopyran-4-yl) -5-carbaRadical-6-
(4-Nitrophenyl) thieno [2,3-d]Synthesis of pyrimidine-2, 4(1H,3H) -diones
This title compound was prepared as described in example 1, step 6 by reacting 3- (1, 1-dioxotetrahydro-2H-thiopyran-4-yl) -5-methyl-6- (4-nitrophenyl) thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -dione (0.85g,1.95mmol), potassium iodide (0.65g,3.9 mmol), potassium carbonate (0.54g,3.9mmol) and 2, 6-difluorobenzyl chloride (0.63g,3.9mmol) in DMF (8mL) and drying to give the title compound as a pale yellow solid (1.01g, 91.8%).
1H NMR(400MHz,CDCl3)δ(ppm)8.30(d,J=8.7Hz,2H),7.54(d,J=8.7Hz,2H),7.34(dd,J=14.8,8.2Hz, 1H),6.95(t,J=8.1Hz,2H),5.35(s,2H),5.19(t,J=12.0Hz,1H),3.54–3.41(m,2H),3.20(d,J=7.6Hz,4H), 2.58(s,3H),2.07–2.01(m,2H).
Step 4)5- (bromomethyl) -1- (2, 6-difluorobenzyl) -3- (1, 1-dioxotetrahydro-2H-thiopyran-4-one- 6- (4-nitrophenyl) thieno-6-yl b2,3-d]Synthesis of pyrimidine-2, 4(1H,3H) -diones
This title compound was prepared as described in example 1, step 7 by reacting 1- (2, 6-difluorobenzyl) -3- (1, 1-dioxotetrahydro-2H-thiopyran-4-yl) -5-methyl-6- (4-nitrophenyl) thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -dione (2.89g,5.15mmol), azobisisobutyronitrile (0.22g,1.29mmol), and N-bromosuccinimide (1.76g,9.79mmol) in chlorobenzene (30mL) to give the title compound as a pale yellow solid (3.26g, 98.8%).
Step 5)1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -3- (1, 1-dioxotetrahydro-2H-thioxo
Pyran-4-yl) -6- (4-nitrophenyl) thieno [2,3-d]Synthesis of pyrimidine-2, 4(1H,3H) -diones
The title compound was prepared as described in example 1, step 8 by reacting 5- (bromomethyl) -1- (2, 6-difluorobenzyl) -3- (1, 1-dioxotetrahydro-2H-thiopyran-4-yl) -6- (4-nitrophenyl) thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -dione (0.57g,0.89 mmol), dimethylamine hydrochloride (0.18g,2.21mmol) and triethylamine (0.37mL,2.67mmol) in DMF (6mL) and the crude product was purified by silica gel column chromatography (dichloromethane/methanol (v/v) 40/1) to give the title compound as a pale yellow solid (0.41g, 75.9%).
MS(ESI,pos.ion)m/z:605.1[M+H]+;
1H NMR(400MHz,CDCl3)δ(ppm)8.29(d,J=8.7Hz,2H),7.80(d,J=8.7Hz,2H),7.35(dt,J=14.7,7.2Hz, 1H),6.95(t,J=8.2Hz,2H),5.34(d,J=14.8Hz,2H),5.20(t,J=11.9Hz,1H),3.76(d,J=5.1Hz,2H),3.27– 3.11(m,4H),2.27(s,2H),2.05(d,J=13.3Hz,2H),1.64(s,6H).
Step 6)6- (4-aminophenyl) -1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -3- (1, 1-bis
Oxotetrahydro-2H-thiopyran-4-yl) thieno [2,3-d]Synthesis of pyrimidine-2, 4(1H,3H) -diones
The title compound was prepared as described in example 1, step 9 by reacting 1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -3- (1, 1-dioxotetrahydro-2H-thiopyran-4-yl) -6- (4-nitrophenyl) thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -dione (0.4g, 0.66mmol), Pd/C (0.15g) and ethyl acetate hydrogen chloride solution (1.0mL,2M) were reacted in methanol (5mL) and the crude product was purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 30/1) to give the title compound as a white solid (0.26g, 68.4%).
MS(ESI,pos.ion)m/z:575.3[M+H]+;
1H NMR(400MHz,CDCl3)δ(ppm)7.35–7.29(m,1H),7.22(d,J=8.3Hz,2H),6.91(t,J=8.1Hz,2H),6.71 (d,J=8.3Hz,2H),5.32(s,2H),5.22(t,J=11.9Hz,1H),3.85(s,2H),3.71(brs,2H),3.45(dd,J=25.0,12.3Hz, 2H),3.24–3.13(m,4H),2.18(s,6H).
Step 7)1- (4- (1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -3- (1, 1-dioxotetrahydro-
2H-Thiopyran-4-yl) -2, 4-dioxo-1, 2,3, 4-tetrahydrothieno [2,3-d]Pyrimidin-6-yl) phenyl) -3-methoxy
Synthesis of ureides
The title compound was prepared as described in example 1, step 10 by reacting 6- (4-aminophenyl) -1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -3- (1, 1-dioxotetrahydro-2H-thiopyran-4-yl) thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -dione (0.3g, 0.52mmol), phenyl N-methoxycarbamate (0.44g,2.61mmol), triethylamine (0.36mL,2.61mmol) in DMF (5mL), and the crude product was purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 20/1) to give the title compound as a white solid (0.15g, 44.3%).
MS(ESI,pos.ion)m/z:648.2[M+H]+;
1H NMR(400MHz,CDCl3)δ(ppm)7.65(s,1H),7.57(d,J=8.5Hz,2H),7.43(d,J=8.4Hz,2H),7.34–7.29 (m,1H),7.22(s,1H),6.93(t,J=8.1Hz,2H),5.33(d,J=4.9Hz,2H),5.22(t,J=11.8Hz,1H),3.84(s,3H), 3.45(d,J=12.2Hz,2H),3.19(d,J=10.6Hz,4H),2.19(s,6H),2.06(d,J=12.0Hz,2H),1.64–1.56(m,2H).
Example Synthesis of 51- (4- (1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -3- (1, 1-dioxotetrahydro-2H-thiopyran-4-yl) -2, 4-dioxo-1, 2,3, 4-tetrahydrothieno [2,3-d ] pyrimidin-6-yl) phenyl) -3-ethylurea
This step titled compound was prepared by the method described in reference to example 1, step 10, namely 6- (4-aminophenyl) -1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -3- (1, 1-dioxotetrahydro-2H-thiopyran-4-yl) thieno [2,3-d ]]Pyrimidine-2, 4(1H,3H) -dione (0.4g, 0.7mmol), ethyl isocyanate (0.15g,2.09mmol), pyridine (0.17mL,2.09mmol) were reacted in tetrahydrofuran (10mL), and the crude product was isolated and purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 20/1) to give the title compound as a white solid (0.26g, 57.9%). MS (ESI, pos. ion) M/z 646.3[ M + H ]]+;
1H NMR(400MHz,CDCl3)δ(ppm)7.49(d,J=8.5Hz,2H),7.35–7.29(m,3H),6.92(t,J=8.2Hz,2H),5.32 (d,J=3.4Hz,2H),5.22(d,J=11.9Hz,1H),3.94(s,2H),3.43(d,J=12.8Hz,2H),3.23–3.11(m,4H),2.34(s, 6H),2.09(d,J=12.4Hz,2H),1.44–1.36(m,2H),1.18(t,J=7.2Hz,3H).
Example Synthesis of 61- (4- (1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -3- (1, 1-dioxotetrahydro-2H-thiopyran-4-yl) -2, 4-dioxo-1, 2,3, 4-tetrahydrothieno [2,3-d ] pyrimidin-6-yl) phenyl) -3-cyclopropylurea
The title compound was prepared as described in example 1, step 10 by reacting 6- (4-aminophenyl) -1- (2, 6-difluorobenzyl) -5- ((dimethylamino) methyl) -3- (1, 1-dioxotetrahydro-2H-thiopyran-4-yl) thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -dione (0.25g, 0.44mmol), phenyl N-cyclopropylcarbamate (0.23g,1.3mmol), triethylamine (0.18mL,1.3mmol) in DMF (5mL), and the crude product was purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 15/1) to give the title compound as a white solid (0.24 g, 82.8%).
MS(ESI,pos.ion)m/z:658.2[M+H]+;
1H NMR(400MHz,CDCl3)δ(ppm)7.52(d,J=8.5Hz,2H),7.40(d,J=8.4Hz,2H),7.09(s,1H),6.92(t,J= 8.1Hz,2H),5.32(d,J=3.0Hz,2H),5.22(t,J=12.0Hz,1H),3.71(s,2H),3.45(d,J=12.5Hz,2H),3.17(brs, 4H),2.92(brs,1H),2.17(s,6H),2.05(d,J=13.1Hz,2H),0.89(d,J=6.2Hz,4H).
Biological assay
Example A: antagonism of humanized GnRH receptors by Compounds of the invention
Purpose of experiment
The antagonism of the compounds of the present invention against the transfected humanized GnRH receptor in RBL-1 cells (rat basophilic leukemia cells) was evaluated by fluorescence detection of cytosolic calcium flux.
Experimental procedure
The cells were suspended in HBSS buffer (Invitrogen ), 20mM HEPES buffer (Invitrogen ), and then diluted at 1.186X 104The density of cells/well is averaged into the microwell reaction plate. After mixing the fluorescent probe (Fluo8Direct, AAT biosquest) with HBSS buffer (20 mM HEPES buffer, PH 7.4 was added), each well was added, and the cells were incubated at 30 ℃ for 60 min. Then the reaction plate is placed in a microplate reader (FlipR Tetra, Molecular Device) for testing, a compound to be tested or HBSS buffer solution (blank control) is added, 8nM LH-RH is added after 5min, and the change of fluorescence intensity which is in direct proportion to the calcium ion concentration in cytoplasm is measured. The inhibition ratio of the compound was calculated with the fluorescence intensity of the blank control group to which no compound was added being 100% (inhibition ratio being 0%). Measuring the inhibition rate of the compound at different concentrations, and calculating the IC50The value is obtained. The results of the experiment are shown in table a below.
TABLE A antagonistic Effect of the Compounds of the invention on humanized GnRH receptors
Example No. 2 | IC50(nM) |
Example 1 | 138.7 |
Example 2 | 110.1 |
Example 3 | 101.8 |
Example 6 | 98.19 |
The experimental result shows that the compound has good antagonistic action on the humanized GnRH receptor.
Example B pharmacokinetic evaluation of the Compounds of the invention after intravenous injection or gavage in rats and dogs
The present invention evaluates the pharmacokinetic studies of the compounds of the invention in rats and/or dogs for details in the animal information given in table B.
Table B information sheet of the subject animals of the present invention
Test method
The compounds of the invention were administered to the test animals as 10% DMSO + 10% Kolliphor HS15+ 78% Saline + 2% (2% HCl) solution or 78% Saline + 2% (2% HCl) + 20% PEG400 solutionThe administration is carried out, and animals are fasted for 12h before administration and have free water. For the group administered by intravenous injection, the dose was 1mg/kg (rat) or 0.5mg/kg (dog), and blood was taken intravenously (blood volume taken was about 0.2mL) at the following time points after administration: 0.083, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0 and 24h (dog) or 0.083, 0.25, 0.5, 1.0, 2.0, 5.0, 7.0 and 24h (rat), EDTA-K is added into the blood sampling tube in advance2Can be used as anticoagulant. For the gavage group, 5mg/kg (rat) or 2.5mg/kg (dog) was administered, and intravenous blood sampling (blood volume taken about 0.2mL) was performed at the following time points after administration: 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0 and 24h (dog) or 0.25, 0.5, 1.0, 2.0, 5.0, 7.0 and 24h (rat), EDTA-K is added into the blood sampling tube in advance2Can be used as anticoagulant. Blood samples were centrifuged at 12,000rpm for 2 minutes, plasma was collected and stored at-20 ℃ or-70 ℃. .
The plasma samples collected above were processed (frozen plasma was thawed at room temperature, vortexed for 15s, 10-20. mu.L of plasma was taken, 120-150. mu.L of acetonitrile solution containing the internal standard was added, vortexed for 5min, centrifuged at 4,000rpm for 5min, 100. mu.L of supernatant was taken, and 120-150. mu.L of methanol/water (v/v. 1/1) was added and mixed) and then the concentration of the compounds in the plasma was analyzed by LC/MS/MS.
The analysis result shows that the compound of the invention has better pharmacokinetic property in rats and/or dogs. The compound of the invention has good drug property and good clinical application prospect.
In the description herein, references to the description of the term "one embodiment," "an embodiment," "some embodiments," "an example," "a specific example" or "some examples" or the like are intended to mean that a particular feature, structure, material, or characteristic described in connection with the embodiment, or example is included in at least one embodiment, or example of the invention. In this specification, a schematic representation of the above terms does not necessarily refer to the same embodiment, implementation, or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments, implementations, or examples. Furthermore, the various examples, embodiments, or examples described in this specification, as well as features of various examples, embodiments, or examples, may be combined and combined by one skilled in the art without contradiction.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention.
Claims (5)
1. A compound which is a compound represented by formula (I) or a tautomer or a pharmaceutically acceptable salt of the compound represented by formula (I),
wherein:
x is O, S, S (═ O) or S (═ O)2;
R1Is cyclopropyl;
each R2a、R2b、R2c、R2d、R6a、R6b、R6cAnd R6dIndependently is H or D;
R3and R4Each independently is H, D or C1-C4An alkyl group;
R5b、R5cand R5dEach independently is H or D;
R5aand R5eEach independently is F.
2. The compound of claim 1, wherein R3And R4Each independently H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, 2-methylpropyl or 1-methylpropyl.
4. a pharmaceutical composition comprising a compound of any one of claims 1-3; and
the pharmaceutical composition optionally further comprises a pharmaceutically acceptable excipient, carrier, adjuvant, or any combination thereof.
5. Use of a compound according to any one of claims 1 to 3 or a pharmaceutical composition according to claim 4 for the manufacture of a medicament for the prevention or treatment of a sex hormone dependent disease;
wherein the sex hormone dependent disease is a sex hormone dependent cancer, bone metastasis of a sex hormone dependent cancer, prostatic hypertrophy, hysteromyoma, endometriosis, uterine fibroids, precocious puberty, amenorrhea, premenstrual syndrome, dysmenorrhea, multi-atrial ovarian syndrome, polycystic ovarian syndrome, acne, alopecia, infertility or irritable bowel syndrome.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010636105.1A CN111875614B (en) | 2020-07-03 | 2020-07-03 | Heterocyclyl-substituted thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -diones and their use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010636105.1A CN111875614B (en) | 2020-07-03 | 2020-07-03 | Heterocyclyl-substituted thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -diones and their use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111875614A CN111875614A (en) | 2020-11-03 |
CN111875614B true CN111875614B (en) | 2022-04-29 |
Family
ID=73150161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010636105.1A Active CN111875614B (en) | 2020-07-03 | 2020-07-03 | Heterocyclyl-substituted thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -diones and their use |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111875614B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112552312B (en) * | 2020-12-07 | 2022-08-05 | 杭州科巢生物科技有限公司 | Synthetic method of Ruogeli or salt thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1768065A (en) * | 2003-01-29 | 2006-05-03 | 武田药品工业株式会社 | Thienopyrimidine compound and use of the same |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7569570B2 (en) * | 2002-01-30 | 2009-08-04 | Takeda Pharmaceutical Company Limited | Thienopyrimidines, process for preparing the same and use thereof |
-
2020
- 2020-07-03 CN CN202010636105.1A patent/CN111875614B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1768065A (en) * | 2003-01-29 | 2006-05-03 | 武田药品工业株式会社 | Thienopyrimidine compound and use of the same |
Also Published As
Publication number | Publication date |
---|---|
CN111875614A (en) | 2020-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111574534B (en) | Phenyl-substituted thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -diones and their use | |
CN111925379B (en) | Nitrogen-containing heteroaryl substituted pyrimidinediones and uses thereof | |
EP2671582B1 (en) | Ring-fused heterocyclic derivative | |
JP6035423B2 (en) | Novel condensed pyrimidine compound or salt thereof | |
CN107635404B (en) | MCT4 inhibitors for the treatment of disease | |
JP2011511003A (en) | Oxime derivatives as HSP90 inhibitors | |
EA015513B1 (en) | Carbonylaminopyrrolopyrazoles as effective kinase inhibitors | |
CN111333587B (en) | Substituted pyrimidine-2, 4 (1H, 3H) -dione derivatives and uses thereof | |
JPH09169768A (en) | Thienopyrimidine derivative, its production and use | |
US20140275711A1 (en) | 1-(Arylmethyl)-5,6,7,8-tetrahydroquinazolline-2,4-diones and Analogs and the Use Thereof | |
CN113754679B (en) | Substituted pyrimidinediones and their use | |
JP2022526854A (en) | Phosphatidylinositol 3-kinase inhibitor | |
JP2004002309A (en) | NON-PEPTIDIC GnRH AGENT, PHARMACEUTICAL COMPOSITION, AND METHOD OF USING THEM | |
TW202400601A (en) | Substituted tricyclic compounds as parp inhibitors and the use thereof | |
US9920066B2 (en) | Thienopyrimidine compounds | |
CN111875614B (en) | Heterocyclyl-substituted thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -diones and their use | |
CN112142757B (en) | Five-membered nitrogen-containing heteroaryl substituted pyrimidinedione compound and application thereof | |
CN111320633A (en) | Pyrrole/imidazo six-membered heteroaromatic ring compound and preparation method and medical application thereof | |
CN111793078B (en) | Bicyclic nitrogen-containing heteroaryl substituted pyrimidinediones and application thereof | |
CN111943960B (en) | Substituted pyrimidinediones and their use | |
TWI638817B (en) | Preventive and / or therapeutic agent for immune diseases | |
CN112041319B (en) | Triazole, imidazole and pyrrole fused piperazine derivatives and their use as mGlu5Use of modulators of receptors | |
CN112047957B (en) | Substituted pyrimidinediones and their use | |
CN111909168B (en) | Nitrogenous heterocyclic group substituted pyrimidinediones and uses thereof | |
CN116096371A (en) | Pyrimidine diketone compound containing saturated oxygen heterocyclic group and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: Room 501, building 4, No.368, middle Zhen'an Road, Chang'an Town, Dongguan City, Guangdong Province, 523871 Patentee after: Dongguan dongyangguang new drug R & D Co.,Ltd. Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd. Address before: Room 501, building 4, No.368, middle Zhen'an Road, Chang'an Town, Dongguan City, Guangdong Province, 523871 Patentee before: Dongguan dongyangguang new drug R & D Co.,Ltd. Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |